Infantile-Onset Pompe Disease

Mendelian MONDO:0017694 Pathograph 30 Show in embeddings browser Pompe Disease Lysosomal Storage Disease

Classic infantile-onset Pompe disease (IOPD) is the most severe form of glycogen storage disease due to acid maltase deficiency, defined by symptom onset before age 12 months together with hypertrophic cardiomyopathy. It is caused by biallelic fully deleterious GAA variants that leave essentially no residual acid alpha-glucosidase activity (typically <1% of control), so lysosomal glycogen accumulates rapidly and massively in cardiac, skeletal, and respiratory muscle. Untreated infants present in the first weeks to months of life with progressive cardiomegaly and hypertrophic cardiomyopathy, profound hypotonia, feeding difficulty and failure to thrive, macroglossia, hepatomegaly, and respiratory distress, and die of cardiopulmonary insufficiency in the first one to two years. Two features distinguish IOPD mechanistically from the late-onset form curated under Pompe Disease. First, the near-total absence of enzyme drives an aggressive cardiac phenotype that late-onset disease does not have. Second, because roughly a quarter of classic infantile patients make no immunologically detectable GAA protein at all (cross-reactive immunologic material, CRIM-negative), recombinant human GAA is seen by the immune system as a foreign protein: these infants mount early, high, sustained anti-rhGAA IgG responses that neutralize enzyme replacement therapy and are associated with death or invasive ventilation despite treatment, unless immune tolerance is induced. Enzyme replacement therapy started early transforms survival and reverses cardiac hypertrophy, and has revealed an emerging long-term survivor phenotype with residual myopathy, hearing loss, dysphagia, osteopenia, and progressive cerebral white-matter abnormalities.

Ask OpenScientist

Ask a research question about Infantile-Onset Pompe Disease. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Definitions
1
Inheritance
10
Pathophys.
18
Phenotypes
1
Gaps
30
Pathograph
1
Genes
7
Medical Actions
2
Trials
1
Models
14
References
1
Deep Research
🏷

Classifications

Harrison's Part
ENDOCRINOLOGY METABOLISM
Lysosomal Storage
disorder of glycogen metabolism
📘

Definitions

1
GeneReviews clinical definition of IOPD
GeneReviews defines infantile-onset Pompe disease by onset before age 12 months together with cardiomyopathy; onset before 12 months WITHOUT cardiomyopathy is classified as late-onset disease. Cardiomyopathy, not age alone, is the discriminating criterion.
CASE_DEFINITION
Show evidence (1 reference)
PMID:20301438 SUPPORT Other
"Pompe disease can be classified by age of onset, organ involvement, severity, and rate of progression into infantile-onset Pompe disease (IOPD) (i.e., individuals with onset before age 12 months with cardiomyopathy)"
States the case definition that separates IOPD from LOPD by the presence of cardiomyopathy in the first year.
👪

Inheritance

1
Autosomal recessive HP:0000007
IOPD is inherited in an autosomal recessive manner, with affected infants carrying two fully deleterious (null or severely damaging) GAA alleles. The severity of the infantile phenotype tracks the near-complete absence of residual enzyme produced by this fully deleterious genotype.
Autosomal recessive inheritance
Show evidence (3 references)
PMID:12897283 SUPPORT Human Clinical
"The patients have fully deleterious mutations. Acid alpha-glucosidase activity is severely deficient."
The natural-history cohort establishes that classic infantile patients carry fully deleterious GAA genotypes with severely deficient enzyme activity.
PMID:22252923 SUPPORT Human Clinical
"We found that, in most cases, CRIM status can be predicted from GAA mutations, potentially circumventing the need for invasive skin biopsy and time wasted in culturing cells in the future."
Shows that the biallelic GAA genotype determines whether any GAA protein is made, i.e. CRIM status.
PMID:20301438 SUPPORT Other
"If both parents are known to be heterozygous for a GAA pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier."
The GeneReviews GENETIC COUNSELING section states the autosomal recessive transmission risks that follow from biallelic GAA inheritance.
?

Discussions and Knowledge Gaps

1
Does the progressive cerebral white-matter abnormality of ERT-treated IOPD survivors reflect ongoing CNS glycogen storage that intravenous rhGAA cannot reach, and would a brain-penetrant therapy prevent it?
KNOWLEDGE GAP OPEN gap_iopd_cns_glycogen_white_matter
Attached to
pathophysiology#Central nervous system glycogen storage and progressive white matter abnormality
The cohort study establishes the white-matter phenotype and its temporal progression but does not demonstrate the storage-to-white-matter mechanism directly, nor is there interventional evidence that reducing CNS glycogen alters the neuropsychological trajectory. The authors explicitly frame the brain as an additional target for next-generation therapy rather than a solved mechanism.
Proposed experiments
Longitudinal CNS glycogen and white-matter imaging in treated IOPD
exp_iopd_cns_glycogen_imaging
Correlate a CNS glycogen-burden measure with serial quantitative white-matter MRI and neuropsychological testing in a multi-centre treated IOPD cohort, and compare against recipients of brain-directed enzyme delivery when such therapy becomes available.
Show evidence (1 reference)
PMID:29573408 SUPPORT Human Clinical
"Therefore, we advise follow-up programs are expanded to capture CNS involvement in larger, international patient cohorts, to incorporate our findings in the counselling of parents before the start of treatment, and to include the brain as an additional target in the development of..."
The authors frame CNS involvement as an open target rather than a resolved mechanism.
⚙

Pathophysiology

10
Near-complete acid alpha-glucosidase deficiency
Biallelic fully deleterious GAA variants abolish acid alpha-glucosidase activity, leaving typically less than 1% of control activity in fibroblasts or muscle. This is the quantitative distinction from late-onset disease, where residual activity is higher and the phenotype correspondingly milder and non-cardiac.
GAA hgnc:4065 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves decreased GAA (hgnc:4065). hgnc:4065 is a gene from the HUGO Gene Nomenclature Committee. ↓ DECREASED
glucosidase activity GO:0015926 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased glucosidase activity (GO:0015926). GO:0015926 is a molecular function from the Gene Ontology. ↓ DECREASED
Downstream
Lysosomal glycogen accumulation Loss of the only lysosomal glycogen-degrading enzyme causes undegraded glycogen to accumulate in the lysosome.
Absence of immunologically detectable GAA protein (CRIM-negative status) Null GAA alleles that produce no protein at all, rather than an inactive protein, yield CRIM-negative status in roughly a quarter of classic infantile patients.
Show evidence (2 references)
PMID:12897283 SUPPORT Human Clinical
"The patients have fully deleterious mutations. Acid alpha-glucosidase activity is severely deficient."
Establishes near-absent enzyme activity as the molecular lesion of the classic infantile form.
PMID:22252923 SUPPORT Human Clinical
"The classical infantile form is rapidly progressive and presents with hypertrophic cardiomyopathy by the first few months of life and has a fatal outcome within the first year of life if left untreated"
Links the severe enzymatic lesion to the rapidly progressive cardiac infantile phenotype.
Lysosomal glycogen accumulation
Undegraded glycogen accumulates progressively within lysosomes of cardiac, skeletal, respiratory, and smooth muscle, and of the central nervous system. In IOPD the accumulation is early and massive because essentially no residual enzyme is available.
Cardiac muscle cell CL:0000746 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Cardiac muscle cell (CL:0000746). CL:0000746 is a cell type from the Cell Ontology. Skeletal muscle fiber CL:0008002 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Skeletal muscle fiber (CL:0008002). CL:0008002 is a cell type from the Cell Ontology.
Glycogen catabolic process GO:0005980 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased Glycogen catabolic process (GO:0005980). GO:0005980 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Cardiomyocyte glycogen storage and progressive hypertrophic remodeling Cardiomyocyte glycogen storage drives the cardiomegaly and hypertrophic cardiomyopathy that define IOPD.
Skeletal and respiratory myofiber injury Storage in skeletal and respiratory myofibers produces the profound hypotonia and respiratory distress of untreated IOPD.
Hepatomegaly Hepatic glycogen storage produces the moderate hepatomegaly of infantile disease. The cited cohort attributes it to storage but does not exclude a contribution from cardiac decompensation, so the edge is a partial rather than sole explanation.
Failure of productive autophagy and autophagic buildup Glycogen-laden lysosomes disrupt lysosome-dependent autophagic flux, so autophagic substrate accumulates in muscle.
Central nervous system glycogen storage and progressive white matter abnormality Glycogen storage is not confined to muscle; CNS storage becomes clinically visible only once ERT allows survival into later childhood.
Show evidence (2 references)
ORPHA:365 SUPPORT Other
"A rare lysosomal storage disease characterized by lysosomal accumulation of glycogen particularly in skeletal, cardiac, and respiratory muscles"
Orphanet records the lysosomal glycogen-accumulation lesion and the tissues in which it occurs.
PMID:12897283 SUPPORT Human Clinical
"Infantile Pompe's disease is a lethal cardiac and muscular disorder."
Identifies cardiac and skeletal muscle as the tissues in which the storage lesion is clinically decisive.
Cardiomyocyte glycogen storage and progressive hypertrophic remodeling
Massive cardiomyocyte glycogen storage produces cardiomegaly and hypertrophic cardiomyopathy that is usually already identifiable in the first weeks of life and progresses to left ventricular outflow obstruction and diminished lung volume. Glycogen deposition in conduction tissue shortens the PR interval. This node is the principal mechanistic difference between IOPD and late-onset Pompe disease, which lacks significant cardiac involvement.
Cardiac muscle cell CL:0000746 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Cardiac muscle cell (CL:0000746). CL:0000746 is a cell type from the Cell Ontology.
Cardiac muscle hypertrophy GO:0003300 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased Cardiac muscle hypertrophy (GO:0003300). GO:0003300 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Hypertrophic cardiomyopathy Cardiomyocyte storage and hypertrophic remodeling manifest clinically as hypertrophic cardiomyopathy.
Shortened PR interval Glycogen deposition in the cardiac conduction system shortens the PR interval on ECG.
Cardiopulmonary insufficiency of infancy Progressive cardiac hypertrophy with outflow obstruction is a principal contributor to fatal cardiopulmonary insufficiency.
Show evidence (2 references)
PMID:20301438 SUPPORT Other
"Cardiomegaly and hypertrophic cardiomyopathy is usually identified in the first weeks of life and progress to left ventricular outflow obstruction and diminished lung volume."
Documents the timing and progression of the cardiac lesion specific to IOPD.
PMID:12897283 SUPPORT Human Clinical
"The diastolic thickness of the left ventricular posterior wall and cardiac weight at autopsy increase significantly with age."
Quantitative natural-history evidence that the cardiac hypertrophy is progressive.
Skeletal and respiratory myofiber injury
Lysosomal glycogen storage in skeletal, respiratory, and bulbar muscle injures myofibers, producing the floppy-infant presentation: generalized hypotonia, severely delayed motor development, feeding difficulty with poor growth, and respiratory distress.
Skeletal muscle fiber CL:0008002 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Skeletal muscle fiber (CL:0008002). CL:0008002 is a cell type from the Cell Ontology.
Downstream
Generalized hypotonia Myofiber injury produces the profound generalized hypotonia of the floppy infant.
Generalized muscle weakness The same myofiber injury produces generalized skeletal muscle weakness, which GeneReviews records as a feature distinct from the accompanying hypotonia.
Motor developmental delay Muscle weakness prevents acquisition of major motor milestones.
Respiratory insufficiency Respiratory myofiber injury, compounded by diminished lung volume from cardiomegaly, causes respiratory distress and insufficiency.
Feeding difficulties Bulbar and generalized muscle weakness impair sucking, swallowing, and feeding.
Failure to thrive Growth deviates significantly from normal even once nasogastric tube feeding is started.
Cardiopulmonary insufficiency of infancy Respiratory muscle failure combines with the cardiac lesion to produce fatal cardiopulmonary insufficiency.
Show evidence (2 references)
PMID:20301438 SUPPORT Other
"Untreated individuals with IOPD typically have hypotonia, generalized muscle weakness, feeding difficulties, poor growth, and respiratory distress."
Lists the untreated IOPD muscle phenotype produced by myofiber injury.
PMID:12897283 SUPPORT Human Clinical
"Motor development is severely delayed and major developmental milestones are generally not achieved."
Natural-history evidence for the severity of the motor consequence of myofiber injury in IOPD.
Cardiopulmonary insufficiency of infancy
The convergence of hypertrophic cardiomyopathy with outflow obstruction and respiratory muscle failure produces cardiopulmonary insufficiency. In the pre-treatment natural history, symptoms began at a median age of 1.6 months and the median age of death was 6-7.7 months, with only 5-8% of infants surviving beyond one year.
Downstream
Death in infancy Untreated, cardiopulmonary insufficiency is fatal in the first one to two years of life.
Show evidence (1 reference)
PMID:12897283 SUPPORT Human Clinical
"Symptoms start at a median age of 1.6 months in both groups. The median age of death is 7.7 and 6 months, respectively. Five percent of the Dutch patients and 8% of all reported patients survive beyond 1 year of age."
Quantifies the untreated natural history of onset and death that this node represents.
Absence of immunologically detectable GAA protein (CRIM-negative status)
CRIM (cross-reactive immunologic material) status asks a different question from enzyme activity: not whether GAA works, but whether any GAA protein is made at all. Patients with two null alleles produce no GAA protein detectable by Western blot and are CRIM-negative; patients producing a catalytically inactive protein are CRIM-positive. Because a CRIM-negative infant has never been immunologically tolerized to GAA, recombinant human GAA is a foreign antigen. Roughly 20-25% of classic infantile patients are CRIM-negative, and CRIM status is largely predictable from the GAA genotype.
GAA hgnc:4065 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves decreased GAA (hgnc:4065). hgnc:4065 is a gene from the HUGO Gene Nomenclature Committee. ↓ DECREASED
Downstream
High sustained anti-rhGAA antibody response Never having been tolerized to endogenous GAA, CRIM-negative infants mount an early, high-titer, sustained IgG response to infused recombinant human GAA.
Show evidence (2 references)
PMID:22252923 SUPPORT Human Clinical
"CRIM-negative patients make no GAA protein and develop sustained high antibody titers to ERT that render the treatment ineffective."
Defines CRIM-negative status as absence of GAA protein and links it to the antibody response.
PMID:19775921 SUPPORT Human Clinical
"Patients synthesize a non-functional form of GAA or are unable to form native enzyme."
States the CRIM-positive versus CRIM-negative molecular distinction.
High sustained anti-rhGAA antibody response
Sustained high-titer neutralizing IgG against recombinant human GAA blocks the therapeutic benefit of enzyme replacement therapy. This is a treatment-conditioned mechanism with no counterpart in late-onset disease, and it is the reason CRIM status must be determined before the first infusion.
humoral immune response mediated by circulating immunoglobulin GO:0002455 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased humoral immune response mediated by circulating immunoglobulin (GO:0002455). GO:0002455 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Enzyme replacement therapy failure and clinical decline Neutralizing antibody renders infused rhGAA ineffective, and treated CRIM-negative infants deteriorate.
Show evidence (1 reference)
PMID:22237443 SUPPORT Human Clinical
"Cross-reactive immunologic material negative (CRIM-negative) Pompe patients develop high-titer antibody to the rhGAA and do poorly."
Establishes the high-titer antibody response and its adverse clinical consequence.
Enzyme replacement therapy failure and clinical decline
In the absence of immune tolerance induction, CRIM-negative infants on ERT decline despite treatment: cardiac function and gross motor development improve significantly less than in CRIM-positive infants, and by roughly 27 months all CRIM-negative patients in the original series were dead or invasively ventilated.
Show evidence (2 references)
PMID:19775921 SUPPORT Human Clinical
"By age 27.1 months, all CRIM-negative patients and 4/21 (19.0%) CRIM-positive patients were deceased or invasively ventilated."
Quantifies the divergent treated outcome by CRIM status.
PMID:19775921 SUPPORT Human Clinical
"Cardiac function and gross motor development improved significantly more in the CRIM-positive group."
Shows the treatment benefit gap attributable to CRIM status.
Failure of productive autophagy and autophagic buildup
Autophagy is lysosome-dependent, so the storage lesion disables it. Autophagic vesicles accumulate in type II-rich muscle fibers, disrupting the contractile apparatus. Critically for IOPD, the autophagic buildup also acts as a sink for infused recombinant enzyme and prevents its efficient delivery to lysosomes - a second, non-immune route to poor ERT response that runs in parallel to the CRIM-negative antibody arm.
Skeletal muscle fiber CL:0008002 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Skeletal muscle fiber (CL:0008002). CL:0008002 is a cell type from the Cell Ontology.
Autophagy GO:0006914 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased Autophagy (GO:0006914). GO:0006914 is a biological process from the Gene Ontology. ↓ DECREASED
Animal models
GAA-knockout mouse Mouse recapitulates Progressive accumulation of autophagic vesicles in type II-rich fibers, with sequestration of infused recombinant enzyme.
Downstream
Skeletal and respiratory myofiber injury Accumulated autophagosomes disrupt the contractile apparatus of muscle fibers.
Enzyme replacement therapy failure and clinical decline Autophagic buildup sequesters infused recombinant enzyme before it reaches the lysosome, degrading ERT response independently of any antibody response.
Show evidence (1 reference)
PMID:20040311 SUPPORT Model Organism
"we present evidence that a failure of productive autophagy in muscle tissue contributes strongly to disease pathology in both patients with Pompe disease and GAA-knockout mice"
States that failed productive autophagy contributes to pathology in patients as well as in the knockout mouse.
Central nervous system glycogen storage and progressive white matter abnormality
Intravenous rhGAA does not cross the blood-brain barrier, so CNS glycogen storage is untreated. As ERT enables survival into later childhood and adulthood, slowly progressive symmetric white-matter abnormalities emerge - periventricular white matter and centrum semiovale from about age 2, then corpus callosum, capsules and subcortical areas after age 8, and brainstem from age 11 - with variable neuropsychological consequences. This is an ERT-era emerging phenotype rather than part of the classical untreated natural history.
Downstream
Cognitive decline and intellectual disability White-matter involvement is accompanied by neuropsychological decline in a subset of long-term survivors.
Show evidence (1 reference)
PMID:29573408 SUPPORT Human Clinical
"From approximately age 2 years onwards, brain MRI showed involvement of the periventricular white matter and centrum semiovale. After 8 years of age, additional white-matter abnormalities occurred in the corpus callosum, internal and external capsule, and subcortical areas. From 11 years of age,..."
Documents the anatomical progression of white-matter abnormality in treated classic infantile patients.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Infantile-Onset Pompe Disease Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

18
Cardiovascular 1
Hypertrophic cardiomyopathy OBLIGATE HP:0001639 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypertrophic cardiomyopathy (HP:0001639), qualified as course progressive. HP:0001639 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (2 references)
PMID:20301438 SUPPORT Other
"Pompe disease can be classified by age of onset, organ involvement, severity, and rate of progression into infantile-onset Pompe disease (IOPD) (i.e., individuals with onset before age 12 months with cardiomyopathy)"
Cardiomyopathy is definitional for IOPD, supporting an obligate frequency.
PMID:12897283 SUPPORT Human Clinical
"A progressive cardiac hypertrophy is characteristic for infantile Pompe's disease."
Natural-history evidence that cardiac hypertrophy is characteristic and progressive.
Digestive 3
Feeding difficulties HP:0011968 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Feeding difficulties (HP:0011968). HP:0011968 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301438 SUPPORT Other
"Untreated individuals with IOPD typically have hypotonia, generalized muscle weakness, feeding difficulties, poor growth, and respiratory distress."
Lists feeding difficulties among the typical untreated IOPD manifestations.
Hepatomegaly HP:0002240 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hepatomegaly (HP:0002240). HP:0002240 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:12897283 SUPPORT Human Clinical
"The moderate enlargement of the liver is assumed to result from glycogen storage, but may also result from cardiac decompensation."
The natural-history cohort reports moderate hepatomegaly and attributes it to glycogen storage with a cardiac contribution.
Dysphagia HP:0002015 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dysphagia (HP:0002015). HP:0002015 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:22538254 SUPPORT Human Clinical
"Commonly present were gross motor weakness, motor speech deficits, sensorineural and/or conductive hearing loss, osteopenia, gastroesophageal reflux, and dysphagia with aspiration risk."
Reports dysphagia with aspiration risk as commonly present in long-term survivors.
Ear 1
Sensorineural hearing impairment HP:0000407 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Sensorineural hearing impairment (HP:0000407). HP:0000407 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:22538254 SUPPORT Human Clinical
"Commonly present were gross motor weakness, motor speech deficits, sensorineural and/or conductive hearing loss, osteopenia, gastroesophageal reflux, and dysphagia with aspiration risk."
Reports hearing loss among the commonly present features of the long-term survivor phenotype.
Head and Neck 1
Macroglossia FREQUENT HP:0000158 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Macroglossia (HP:0000158). HP:0000158 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:12897283 SUPPORT Human Clinical
"An enlarged tongue was noticed in 45% of the Dutch patients and 29% of the cases from literature."
Natural-history cohort quantifies tongue enlargement at 45% in the prospectively examined Dutch series, within the FREQUENT band (79-30%); the 29% literature figure is a retrospective case-note count and is treated as under-ascertainment rather than as a competing estimate.
PMID:20301438 SUPPORT Other
"tracheostomy may be considered in those with macroglossia and severe respiratory insufficiency"
GeneReviews management guidance treats macroglossia as a recognised IOPD feature with airway consequences.
Metabolism 1
Elevated creatine kinase Elevated circulating creatine kinase concentration HP:0003236 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Elevated circulating creatine kinase concentration (HP:0003236). HP:0003236 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:12897283 SUPPORT Human Clinical
"Levels of aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, creatine kinase, or creatine kinase-myocardial band isoenzyme are typically elevated"
Directly reports elevated CK and CK-MB in the infantile natural-history cohort.
Musculoskeletal 4
Generalized hypotonia VERY_FREQUENT HP:0001252 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypotonia (HP:0001252). HP:0001252 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301438 SUPPORT Other
"Untreated individuals with IOPD typically have hypotonia, generalized muscle weakness, feeding difficulties, poor growth, and respiratory distress."
GeneReviews lists hypotonia as a typical untreated IOPD feature, supporting a very frequent band.
Generalized muscle weakness VERY_FREQUENT HP:0003324 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Generalized muscle weakness (HP:0003324). HP:0003324 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301438 SUPPORT Other
"Untreated individuals with IOPD typically have hypotonia, generalized muscle weakness, feeding difficulties, poor growth, and respiratory distress."
GeneReviews lists generalized muscle weakness as a typical untreated IOPD feature, distinct from the hypotonia named in the same sentence, supporting a very frequent band.
Respiratory insufficiency Respiratory insufficiency due to muscle weakness HP:0002747 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Respiratory insufficiency due to muscle weakness (HP:0002747). HP:0002747 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:20301438 SUPPORT Other
"Untreated individuals with IOPD typically have hypotonia, generalized muscle weakness, feeding difficulties, poor growth, and respiratory distress."
GeneReviews names respiratory distress directly among the typical untreated IOPD features.
PMID:20301438 SUPPORT Other
"Cardiomegaly and hypertrophic cardiomyopathy is usually identified in the first weeks of life and progress to left ventricular outflow obstruction and diminished lung volume."
Supports the second clause of the description - that the cardiac lesion compounds the respiratory burden by reducing lung volume.
Osteopenia HP:0000938 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Osteopenia (HP:0000938). HP:0000938 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:22538254 SUPPORT Human Clinical
"Residual muscle weakness, hearing loss, risk for arrhythmias, hypernasal speech, dysphagia with risk for aspiration, and osteopenia were commonly observed findings."
Lists osteopenia among the commonly observed findings in long-term survivors.
Nervous System 3
Motor developmental delay VERY_FREQUENT Motor delay HP:0001270 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Motor delay (HP:0001270). HP:0001270 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:12897283 SUPPORT Human Clinical
"Motor development is severely delayed and major developmental milestones are generally not achieved."
Natural-history cohort reports severe motor delay as a general feature, supporting a very frequent band.
Abnormal cerebral white matter morphology HP:0002500 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormal cerebral white matter morphology (HP:0002500), qualified as course progressive. HP:0002500 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (1 reference)
PMID:29573408 SUPPORT Human Clinical
"From approximately age 2 years onwards, brain MRI showed involvement of the periventricular white matter and centrum semiovale."
Documents the white-matter abnormality and its age of appearance in treated classic infantile patients.
Cognitive decline and intellectual disability HP:0001249 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Intellectual disability (HP:0001249). HP:0001249 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:29573408 SUPPORT Human Clinical
"Cognitive development ranged from stable and normal to declines that lead to intellectual disabilities."
Reports the range of cognitive outcomes, supporting a variably present phenotype.
Growth 1
Failure to thrive HP:0001508 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Failure to thrive (HP:0001508). HP:0001508 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:12897283 SUPPORT Human Clinical
"For the Dutch patient group, growth deviates significantly from normal despite start of nasogastric tube feeding."
Documents growth failure persisting despite feeding support.
Other 3
Shortened PR interval HP:0005165 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Shortened PR interval (HP:0005165). HP:0005165 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301438 SUPPORT Other
"Progressive deposition of glycogen results in conduction defects with shortening of the PR interval on EKG."
Directly documents the shortened PR interval in Pompe disease.
Death in infancy
Deliberately left without a phenotype_term. `HP:0001522` (Death in infancy) is the exact concept, but it sits under `HP:0040006` (Mortality/Aging) rather than `HP:0000118` (Phenotypic abnormality), so it is not a legal PhenotypeTerm value in this schema. No mortality term reachable from HP:0000118 expresses it, and no term beats a wrong one.
Show evidence (2 references)
PMID:20301438 SUPPORT Other
"In untreated infants, death commonly occurs in the first two years of life from cardiopulmonary insufficiency."
States the untreated mortality outcome and its cause.
PMID:12897283 SUPPORT Human Clinical
"The median age of death is 7.7 and 6 months, respectively. Five percent of the Dutch patients and 8% of all reported patients survive beyond 1 year of age."
Quantifies median age at death and one-year survival in the untreated natural history.
Hypernasal speech HP:0001611 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypernasal speech (HP:0001611). HP:0001611 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:22538254 SUPPORT Human Clinical
"Residual muscle weakness, hearing loss, risk for arrhythmias, hypernasal speech, dysphagia with risk for aspiration, and osteopenia were commonly observed findings."
Lists hypernasal speech among commonly observed long-term survivor findings.
🧬

Genetic Associations

1
GAA
Gene: GAA hgnc:4065 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is GAA (hgnc:4065). hgnc:4065 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Show evidence (6 references)
PMID:12897283 SUPPORT Human Clinical
"The patients have fully deleterious mutations. Acid alpha-glucosidase activity is severely deficient."
Establishes fully deleterious biallelic GAA genotypes as the genetic basis of classic infantile disease.
PMID:22252923 SUPPORT Human Clinical
"We found that, in most cases, CRIM status can be predicted from GAA mutations, potentially circumventing the need for invasive skin biopsy and time wasted in culturing cells in the future."
Supports genotype-based prediction of CRIM status from GAA variants.
PMID:39482698 SUPPORT Other
"The GAA gene is localized on chromosome 17 at the 17q25.2–q25.3 locus and contains 20 exons including the 19 coding ones"
Establishes the GAA locus and exon structure.
+ 3 more references
💊

Medical Actions

7
Enzyme replacement therapy with alglucosidase alfa
Action: enzyme replacement therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is enzyme replacement therapy, annotated with Protein Replacement Therapy (NCIT:C16221). NCIT:C16221 is a clinical intervention from the NCI Thesaurus. Ontology label: Protein Replacement Therapy NCIT:C16221
Agent: alglucosidase alfa NCIT:C65221 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses alglucosidase alfa (NCIT:C65221). NCIT:C65221 is a therapeutic agent from the NCI Thesaurus.
Intravenous recombinant human GAA is the disease-specific therapy for IOPD. Initiated before age six months and before the need for ventilatory assistance, it improves survival and ventilator-independent survival, reduces cardiac mass, and substantially improves motor skill acquisition. High-dose ERT started immediately on a newborn-screening diagnosis gives the best reported outcomes.
Mechanism Target:
INHIBITS Lysosomal glycogen accumulation — Infused recombinant human GAA supplies the missing lysosomal enzyme and clears stored glycogen.
Show evidence (1 reference)
PMID:20301438 SUPPORT Other
"In those in whom enzyme replacement therapy (ERT) is initiated before age six months and before the need for ventilatory assistance, a majority have improved survival, improved ventilator-independent survival, reduced cardiac mass, and significantly improved acquisition of motor skills compared..."
Reduced cardiac mass and improved survival evidence the reversal of the storage lesion by ERT.
Target Phenotypes: Hypertrophic cardiomyopathy HP:0001639 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Hypertrophic cardiomyopathy (HP:0001639). HP:0001639 is a phenotype from the Human Phenotype Ontology. Motor delay HP:0001270 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Motor delay (HP:0001270). HP:0001270 is a phenotype from the Human Phenotype Ontology.
Show evidence (3 references)
PMID:17151339 SUPPORT Human Clinical
"All patients (100%) survived to 18 months of age. A Cox proportional hazards analysis demonstrated that treatment reduced the risk of death by 99%, reduced the risk of death or invasive ventilation by 92%, and reduced the risk of death or any type of ventilation by 88%, as compared to an..."
Pivotal trial quantifies the survival benefit of rhGAA in infantile-onset disease.
PMID:32373469 SUPPORT Human Clinical
"High-dose ERT instituted immediately at newborn screening seems to give the best outcome, and a dosage increase is necessary upon - or, even better, before - a rise in biomarker levels."
Real-world cohort supports early, high-dose ERT initiation at newborn screening.
PMID:32373469 SUPPORT Human Clinical
"In patients with classical IOPD diagnosed through newborn screening, those late in ERT initiation (p = .006) or late in high-dosage ERT initiation (p = .044) had a higher risk of motor decline."
Quantifies the penalty of delayed ERT initiation on motor outcome in classic IOPD.
Avalglucosidase alfa
Action: enzyme replacement therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is enzyme replacement therapy, annotated with Protein Replacement Therapy (NCIT:C16221). NCIT:C16221 is a clinical intervention from the NCI Thesaurus. Ontology label: Protein Replacement Therapy NCIT:C16221
Agent: avalglucosidase alfa NCIT:C169795 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses avalglucosidase alfa (NCIT:C169795). NCIT:C169795 is a therapeutic agent from the NCI Thesaurus.
A next-generation recombinant human GAA with enhanced mannose-6-phosphate receptor binding. In the Mini-COMET phase 2 trial, children with IOPD who had declined or responded suboptimally to alglucosidase alfa were switched to avalglucosidase alfa, with persistent normalization of left ventricular mass z score, falling disease-burden biomarkers, and improved or stable motor function through 97 weeks.
Mechanism Target:
INHIBITS Lysosomal glycogen accumulation — Avalglucosidase alfa delivers recombinant GAA to the lysosome via enhanced mannose-6-phosphate receptor uptake.
Show evidence (1 reference)
PMID:40449831 SUPPORT Human Clinical
"Compared with baseline, biomarkers of Pompe disease burden decreased, and motor function improved or stabilized."
Falling disease-burden biomarkers evidence reduction of the glycogen storage lesion.
Target Phenotypes: Hypertrophic cardiomyopathy HP:0001639 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Hypertrophic cardiomyopathy (HP:0001639). HP:0001639 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:40449831 SUPPORT Human Clinical
"Echocardiography revealed persistent left ventricular mass z score normalization. Compared with baseline, biomarkers of Pompe disease burden decreased, and motor function improved or stabilized."
Mini-COMET reports cardiac, biomarker, and motor outcomes for avalglucosidase alfa in IOPD.
Immune tolerance induction with rituximab and methotrexate
Action: immune tolerance inductionNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is immune tolerance induction, annotated with Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. Ontology label: Pharmacotherapy NCIT:C15986
Agent: rituximab NCIT:C1702 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses rituximab (NCIT:C1702). NCIT:C1702 is a therapeutic agent from the NCI Thesaurus. methotrexate NCIT:C642 NCI Thesaurus (NCIT) Relation: this treatment uses this therapeutic agent This treatment uses methotrexate (NCIT:C642). NCIT:C642 is a therapeutic agent from the NCI Thesaurus.
Because CRIM-negative infants neutralize rhGAA, immune tolerance induction is given prophylactically at ERT initiation, or therapeutically once antibodies appear. Rituximab (anti-CD20 B-cell depletion) plus methotrexate, with or without intravenous immunoglobulin, eliminated established anti-rhGAA antibody and conferred durable tolerance off all immune therapy with B-cell recovery. It is most effective before an entrenched high-titer response develops, which is why CRIM status should be known before the first infusion.
Mechanism Target:
INHIBITS High sustained anti-rhGAA antibody response — B-cell depletion plus antimetabolite immunomodulation prevents or eliminates the neutralizing anti-rhGAA IgG response.
Show evidence (1 reference)
PMID:22237443 SUPPORT Human Clinical
"In both patients treated therapeutically, anti-rhGAA was eliminated after 3 and 19 months. All four patients are immune tolerant to rhGAA, off immune therapy, showing B-cell recovery while continuing to receive ERT"
Directly evidences elimination of the antibody response and durable tolerance.
Show evidence (2 references)
PMID:22237443 SUPPORT Human Clinical
"All patients show clinical response to ERT, in stark contrast to the rapid deterioration of their nontolerized CRIM-negative counterparts."
Contrasts tolerized with non-tolerized CRIM-negative infants, supporting the clinical value of tolerance induction.
PMID:20301438 SUPPORT Other
"individuals who do not produce CRIM (i.e., who are CRIM negative) generally develop high titer anti-rhGAA antibodies during ERT and require modified therapy protocols using immunomodulation early in the treatment course, optimally before the first infusion."
Management guidance specifying immunomodulation for CRIM-negative infants, optimally before the first infusion.
Intravenous immunoglobulin adjunct
Action: immunoglobulin therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is immunoglobulin therapy (NCIT:C62710). NCIT:C62710 is a clinical intervention from the NCI Thesaurus. Ontology label: Immunoglobulin Therapy NCIT:C62710
Intravenous gammaglobulin was used alongside rituximab and methotrexate in the therapeutic (post-antibody) tolerance-induction regimen; the prophylactic regimen given at ERT initiation used a short rituximab-plus-methotrexate course essentially without IVIG.
Mechanism Target:
INHIBITS High sustained anti-rhGAA antibody response — IVIG was part of the therapeutic tolerance-induction combination that eliminated established anti-rhGAA antibody.
Show evidence (1 reference)
PMID:22237443 SUPPORT Human Clinical
"The combination of rituximab with methotrexate ± intravenous gammaglobulins (IVIG) is an option for tolerance induction of CRIM-negative Pompe to ERT when instituted in the naïve setting or following antibody development."
Names IVIG as a component of the tolerance-induction combination.
Show evidence (1 reference)
PMID:22237443 SUPPORT Human Clinical
"Two CRIM-negative patients with preexisting anti-GAA antibodies were treated therapeutically with rituximab, methotrexate, and gammaglobulins."
Describes the therapeutic regimen in which IVIG was used.
Respiratory support
Action: artificial respirationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is artificial respiration, annotated with Mechanical Ventilation (NCIT:C70909). NCIT:C70909 is a clinical intervention from the NCI Thesaurus. Ontology label: Mechanical Ventilation NCIT:C70909
Respiratory support for respiratory insufficiency may include CPAP and BiPAP; tracheostomy may be considered in infants with macroglossia and severe respiratory insufficiency. Invasive ventilator-free survival is the primary outcome measure in IOPD trials.
Target Phenotypes: Respiratory insufficiency due to muscle weakness HP:0002747 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Respiratory insufficiency due to muscle weakness (HP:0002747). HP:0002747 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301438 SUPPORT Other
"Respiratory support for those with respiratory insufficiency may include CPAP and BiPAP; tracheostomy may be considered in those with macroglossia and severe respiratory insufficiency."
Specifies the respiratory support options in Pompe disease management.
Feeding therapy and gastrostomy
Action: Dietary managementNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Dietary management, annotated with Dietary Intervention (NCIT:C15447). NCIT:C15447 is a clinical intervention from the NCI Thesaurus. Ontology label: Dietary Intervention NCIT:C15447
Feeding therapy with consideration of a gastrostomy tube is recommended for infants with feeding and nutritional difficulties, though growth may still deviate from normal despite tube feeding.
Target Phenotypes: Feeding difficulties HP:0011968 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Feeding difficulties (HP:0011968). HP:0011968 is a phenotype from the Human Phenotype Ontology. Failure to thrive HP:0001508 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Failure to thrive (HP:0001508). HP:0001508 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20301438 SUPPORT Other
"Feeding therapy and consideration of a gastrostomy tube is recommended for those who have feeding/nutritional difficulties."
States the recommended feeding intervention.
Cardiac management with Pompe-specific drug precautions
Action: supportive careNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is supportive care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. Ontology label: Supportive Care NCIT:C15747
Medical intervention for cardiomyopathy must be individualized because standard cardiac drugs may be contraindicated at certain disease stages; digoxin, inotropes, diuretics, and afterload-reducing agents may worsen left ventricular outflow obstruction.
Target Phenotypes: Hypertrophic cardiomyopathy HP:0001639 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Hypertrophic cardiomyopathy (HP:0001639). HP:0001639 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:20301438 SUPPORT Other
"The use of digoxin, ionotropes, diuretics, and afterload-reducing agents may worsen left ventricular outflow"
Lists cardiac drugs that may worsen outflow obstruction in Pompe disease.
PMID:39482698 SUPPORT Other
"ECG and Echocardiogram should be performed at diagnosis, and at regular intervals (every 12 months or more frequently, depending on patients’ conditions, in the presence of cardiomyopathy)."
The MetabERN European clinical pathway recommendations set the cardiac surveillance schedule that accompanies this individualized cardiac management.
🔬

Biochemical Markers

3
Acid alpha-glucosidase enzyme activity
Context: Diagnosis rests on deficient GAA enzyme activity in isolated lymphocytes or mixed leukocytes (or fibroblasts/muscle), with classic infantile patients showing severely deficient activity, typically less than 1% of the control mean.
Show evidence (2 references)
PMID:20301438 SUPPORT Other
"The diagnosis of Pompe disease is established in a proband who has deficiency of acid alpha-glucosidase (GAA) enzyme activity in isolated lymphocytes or mixed leukocytes"
States the diagnostic enzyme assay for Pompe disease.
PMID:12897283 SUPPORT Human Clinical
"Acid alpha-glucosidase activity is severely deficient."
Confirms severe enzyme deficiency in the classic infantile cohort.
Urinary glucose tetrasaccharide (Glc4/Hex4)
Context: Urinary glucose tetrasaccharide is a glycogen-burden biomarker used to monitor treatment response in IOPD. Together with creatine kinase, low levels correlate with favourable response to enzyme replacement therapy, and uGlc4 is the more stable of the two.
Show evidence (1 reference)
PMID:32373469 SUPPORT Human Clinical
"Low CK and uGlc4 levels were correlated with favorable response to ERT in IOPD patients, although CK may be more fluctuated than uGlc4."
Establishes urinary Glc4 as a monitoring biomarker of ERT response in IOPD.
Anti-rhGAA IgG antibody titer
Context: Serial anti-recombinant-human-GAA IgG titers stratify treatment response. CRIM-negative infants develop earlier, higher, and more sustained titers; by contrast, long-term survivors of IOPD had low or undetectable anti-alglucosidase alfa antibody titers.
Show evidence (2 references)
PMID:19775921 SUPPORT Human Clinical
"IgG antibodies to rhGAA developed earlier and serotiters were higher and more sustained in the CRIM-negative group."
Reports the antibody-titer difference by CRIM status that makes this a decision-relevant biomarker.
PMID:22538254 SUPPORT Human Clinical
"All long-term survivors had low or undetectable anti-alglucosidase alfa antibody titers."
Shows the association between low antibody titer and long-term survival on ERT.
📊

Prevalence

1
Global live births
Birth Prevalence 1.0 per 100,000 (0.5–1.5) 1–9 per 1,000,000
Pooled global birth prevalence of infantile-onset Pompe disease specifically, from a 2024 systematic review and meta-analysis (1.0 per 100,000 live births, 95% CI 0.5-1.5), against 2.0 per 100,000 for Pompe disease overall.
Show evidence (1 reference)
PMID:39424261 SUPPORT Human Clinical
"Global birth prevalence of infantile-onset Pompe disease was 1.0 cases (95% CI: 0.5-1.5) per 100,000 live births."
Meta-analysis reports the birth prevalence of the infantile-onset form specifically.
🔬

Clinical Trials

2
NCT03019406 PHASE_II ACTIVE_NOT_RECRUITING
Mini-COMET: a phase 2, open-label, ascending-dose, three-cohort study of avalglucosidase alfa in children with infantile-onset Pompe disease who were declining or responding suboptimally to prior alglucosidase alfa.
Target Phenotypes: Hypertrophic cardiomyopathy HP:0001639 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Hypertrophic cardiomyopathy (HP:0001639). HP:0001639 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:40449831 SUPPORT Human Clinical
"The Mini-COMET clinical trial, a phase 2, open-label, ascending-dose, 3-cohort study, has a 25-week primary analysis period (PAP) and an extension treatment period (ETP)."
Describes the design of the registered Mini-COMET trial in infantile-onset Pompe disease.
NCT04910776 PHASE_III ACTIVE_NOT_RECRUITING
Baby-COMET: a phase 3, open-label, single-group study of avalglucosidase alfa in treatment-naive pediatric participants with infantile-onset Pompe disease. It is the first-line counterpart of Mini-COMET, which enrolled only children already declining on alglucosidase alfa, and so speaks to whether avalglucosidase alfa is an alternative to alglucosidase alfa at diagnosis rather than a salvage option.
Target Phenotypes: Hypertrophic cardiomyopathy HP:0001639 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Hypertrophic cardiomyopathy (HP:0001639). HP:0001639 is a phenotype from the Human Phenotype Ontology. Generalized muscle weakness HP:0003324 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Generalized muscle weakness (HP:0003324). HP:0003324 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
clinicaltrials:NCT04910776 SUPPORT Human Clinical
"This is a single group, treatment, Phase 3, open-label study to assess efficacy, safety, pharmacokinetic (PK), pharmacodynamics (PD) of avalglucosidase alfa in treatment-naïve male and female participants with IOPD."
The registry record establishes the phase, design, and treatment-naive IOPD population of the trial.
🐁

Animal Models

1
GAA-knockout mouse
The GAA-knockout mouse reproduces the lysosomal glycogen storage lesion and was the system in which the autophagic-buildup arm of Pompe muscle pathology, and its interference with enzyme replacement therapy, was established.
Species
Mouse
Genotype
Gaa knockout (GAA-null)
Publication
PMID:20040311
Pathograph links
Failure of productive autophagy and autophagic buildup recapitulates fidelity: moderate Progressive accumulation of autophagic vesicles in type II-rich fibers, with sequestration of infused recombinant enzyme.
Limitations: The autophagic buildup in this model is restricted to type II-rich fibers, and mouse and human skeletal muscle differ in fiber-type composition, so the proportion of muscle affected does not transfer directly. The model is also not specific to the infantile form: it models GAA deficiency, not the age of onset or cardiac severity that defines IOPD, and it says nothing about CRIM status, the other determinant of ERT response in infants.
Readouts
Autophagic vesicle accumulation in type II-rich muscle fibers
Direction: INCREASED
Interpretation: Histological correlate of the autophagic-buildup node in this model.
Show evidence (1 reference)
PMID:20040311 SUPPORT Model Organism
"In the GAA-knockout mouse model, progressive accumulation of autophagic vesicles is restricted to Type II-rich muscle fibers."
Reports the measurement and its direction in the knockout mouse.
Show evidence (1 reference)
PMID:20040311 SUPPORT Model Organism
"we present evidence that a failure of productive autophagy in muscle tissue contributes strongly to disease pathology in both patients with Pompe disease and GAA-knockout mice"
Supports treating the knockout mouse as informative for the autophagy node in human disease.
Show evidence (1 reference)
PMID:20040311 SUPPORT Model Organism
"Not only does this build-up of autophagosomes disrupt the contractile apparatus in the muscle fibers, it also interferes with enzyme replacement therapy by acting as a sink for the recombinant enzyme and preventing its efficient delivery to the lysosomes."
Reports the knockout-mouse finding that makes this model informative here - autophagic buildup both damages the contractile apparatus and sequesters infused recombinant enzyme.
{ }

Source YAML

click to show 
name: Infantile-Onset Pompe Disease
creation_date: '2026-08-18T00:00:00Z'
category: Mendelian
description: >
  Classic infantile-onset Pompe disease (IOPD) is the most severe form of glycogen
  storage disease due to acid maltase deficiency, defined by symptom onset before
  age 12 months together with hypertrophic cardiomyopathy. It is caused by
  biallelic fully deleterious GAA variants that leave essentially no residual acid
  alpha-glucosidase activity (typically <1% of control), so lysosomal glycogen
  accumulates rapidly and massively in cardiac, skeletal, and respiratory muscle.
  Untreated infants present in the first weeks to months of life with progressive
  cardiomegaly and hypertrophic cardiomyopathy, profound hypotonia, feeding
  difficulty and failure to thrive, macroglossia, hepatomegaly, and respiratory
  distress, and die of cardiopulmonary insufficiency in the first one to two years.
  Two features distinguish IOPD mechanistically from the late-onset form curated
  under Pompe Disease. First, the near-total absence of enzyme drives an aggressive
  cardiac phenotype that late-onset disease does not have. Second, because roughly a
  quarter of classic infantile patients make no immunologically detectable GAA
  protein at all (cross-reactive immunologic material, CRIM-negative), recombinant
  human GAA is seen by the immune system as a foreign protein: these infants mount
  early, high, sustained anti-rhGAA IgG responses that neutralize enzyme replacement
  therapy and are associated with death or invasive ventilation despite treatment,
  unless immune tolerance is induced. Enzyme replacement therapy started early
  transforms survival and reverses cardiac hypertrophy, and has revealed an emerging
  long-term survivor phenotype with residual myopathy, hearing loss, dysphagia,
  osteopenia, and progressive cerebral white-matter abnormalities.
disease_term:
  preferred_term: Infantile-onset Pompe disease
  term:
    id: MONDO:0017694
    label: glycogen storage disease due to acid maltase deficiency, infantile onset
classifications:
  harrisons_chapter:
  - classification_value: ENDOCRINOLOGY_METABOLISM
    evidence:
    - reference: PMID:22252923
      reference_title: "Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Pompe disease (Glycogen Storage Disease type II; acid maltase deficiency; OMIM# 232300) is an autosomal recessive disorder of glycogen metabolism caused by deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA)"
      explanation: Identifies the disease as an inherited disorder of glycogen metabolism, placing it in the metabolic chapter.
  lysosomal_storage_category:
    classification_value: disorder of glycogen metabolism
    evidence:
    - reference: ORPHA:365
      reference_title: "Glycogen storage disease due to acid maltase deficiency"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "A rare lysosomal storage disease characterized by lysosomal accumulation of glycogen particularly in skeletal, cardiac, and respiratory muscles"
      explanation: Orphanet classifies acid maltase deficiency, of which IOPD is the infantile form, as a lysosomal glycogen-storage disorder.
definitions:
- name: GeneReviews clinical definition of IOPD
  definition_type: CASE_DEFINITION
  derivation_basis: ESTABLISHED_CRITERIA
  description: >
    GeneReviews defines infantile-onset Pompe disease by onset before age 12 months
    together with cardiomyopathy; onset before 12 months WITHOUT cardiomyopathy is
    classified as late-onset disease. Cardiomyopathy, not age alone, is the
    discriminating criterion.
  evidence:
  - reference: PMID:20301438
    reference_title: "Pompe Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Pompe disease can be classified by age of onset, organ involvement, severity, and rate of progression into infantile-onset Pompe disease (IOPD) (i.e., individuals with onset before age 12 months with cardiomyopathy)"
    explanation: States the case definition that separates IOPD from LOPD by the presence of cardiomyopathy in the first year.
parents:
- Pompe Disease
- Lysosomal Storage Disease
inheritance:
- name: Autosomal recessive
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >
    IOPD is inherited in an autosomal recessive manner, with affected infants
    carrying two fully deleterious (null or severely damaging) GAA alleles. The
    severity of the infantile phenotype tracks the near-complete absence of residual
    enzyme produced by this fully deleterious genotype.
  evidence:
  - reference: PMID:12897283
    reference_title: "The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patients have fully deleterious mutations. Acid alpha-glucosidase activity is severely deficient."
    explanation: The natural-history cohort establishes that classic infantile patients carry fully deleterious GAA genotypes with severely deficient enzyme activity.
  - reference: PMID:22252923
    reference_title: "Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We found that, in most cases, CRIM status can be predicted from GAA mutations, potentially circumventing the need for invasive skin biopsy and time wasted in culturing cells in the future."
    explanation: Shows that the biallelic GAA genotype determines whether any GAA protein is made, i.e. CRIM status.
  - reference: PMID:20301438
    reference_title: "Pompe Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "If both parents are known to be heterozygous for a GAA pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier."
    explanation: The GeneReviews GENETIC COUNSELING section states the autosomal recessive transmission risks that follow from biallelic GAA inheritance.
prevalence:
- population: Global live births
  measure_type: BIRTH_PREVALENCE
  prevalence_class: BAND_1_9_PER_1000000
  rate_per_100000: 1.0
  rate_low: 0.5
  rate_high: 1.5
  notes: >-
    Pooled global birth prevalence of infantile-onset Pompe disease specifically,
    from a 2024 systematic review and meta-analysis (1.0 per 100,000 live births,
    95% CI 0.5-1.5), against 2.0 per 100,000 for Pompe disease overall.
  evidence:
  - reference: PMID:39424261
    reference_title: "Global birth prevalence of Pompe disease: A systematic review and meta-analysis"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Global birth prevalence of infantile-onset Pompe disease was 1.0 cases (95% CI: 0.5-1.5) per 100,000 live births."
    explanation: Meta-analysis reports the birth prevalence of the infantile-onset form specifically.
pathophysiology:
- name: Near-complete acid alpha-glucosidase deficiency
  biological_scale: MOLECULAR
  description: >
    Biallelic fully deleterious GAA variants abolish acid alpha-glucosidase activity,
    leaving typically less than 1% of control activity in fibroblasts or muscle. This
    is the quantitative distinction from late-onset disease, where residual activity
    is higher and the phenotype correspondingly milder and non-cardiac.
  gene:
    preferred_term: GAA
    description: Acid alpha-glucosidase, the lysosomal enzyme that hydrolyzes alpha-1,4 and alpha-1,6 glycosidic linkages in glycogen.
    modifier: DECREASED
    term:
      id: hgnc:4065
      label: GAA
  molecular_functions:
  - preferred_term: glucosidase activity
    modifier: DECREASED
    term:
      id: GO:0015926
      label: glucosidase activity
  evidence:
  - reference: PMID:12897283
    reference_title: "The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patients have fully deleterious mutations. Acid alpha-glucosidase activity is severely deficient."
    explanation: Establishes near-absent enzyme activity as the molecular lesion of the classic infantile form.
  - reference: PMID:22252923
    reference_title: "Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The classical infantile form is rapidly progressive and presents with hypertrophic cardiomyopathy by the first few months of life and has a fatal outcome within the first year of life if left untreated"
    explanation: Links the severe enzymatic lesion to the rapidly progressive cardiac infantile phenotype.
  downstream:
  - target: Lysosomal glycogen accumulation
    description: Loss of the only lysosomal glycogen-degrading enzyme causes undegraded glycogen to accumulate in the lysosome.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:22252923
      reference_title: "Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Pompe disease (Glycogen Storage Disease type II; acid maltase deficiency; OMIM# 232300) is an autosomal recessive disorder of glycogen metabolism caused by deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA)"
      explanation: States the enzyme-deficiency-to-glycogen-storage relationship that defines the disease.
  - target: Absence of immunologically detectable GAA protein (CRIM-negative status)
    description: >
      Null GAA alleles that produce no protein at all, rather than an inactive protein,
      yield CRIM-negative status in roughly a quarter of classic infantile patients.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:22252923
      reference_title: "Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "CRIM-negative patients make no GAA protein and develop sustained high antibody titers to ERT that render the treatment ineffective."
      explanation: Directly links the null genotype to absence of GAA protein and CRIM-negative status.
- name: Lysosomal glycogen accumulation
  biological_scale: CELLULAR
  conforms_to: "lysosomal_substrate_accumulation#Lysosomal Substrate Accumulation"
  description: >
    Undegraded glycogen accumulates progressively within lysosomes of cardiac,
    skeletal, respiratory, and smooth muscle, and of the central nervous system. In
    IOPD the accumulation is early and massive because essentially no residual enzyme
    is available.
  cell_types:
  - preferred_term: Cardiac muscle cell
    term:
      id: CL:0000746
      label: cardiac muscle cell
  - preferred_term: Skeletal muscle fiber
    term:
      id: CL:0008002
      label: skeletal muscle fiber
  biological_processes:
  - preferred_term: Glycogen catabolic process
    modifier: DECREASED
    term:
      id: GO:0005980
      label: glycogen catabolic process
  chemical_entities:
  - preferred_term: glycogen
    modifier: INCREASED
    term:
      id: CHEBI:28087
      label: glycogen
  evidence:
  - reference: ORPHA:365
    reference_title: "Glycogen storage disease due to acid maltase deficiency"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "A rare lysosomal storage disease characterized by lysosomal accumulation of glycogen particularly in skeletal, cardiac, and respiratory muscles"
    explanation: Orphanet records the lysosomal glycogen-accumulation lesion and the tissues in which it occurs.
  - reference: PMID:12897283
    reference_title: "The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Infantile Pompe's disease is a lethal cardiac and muscular disorder."
    explanation: Identifies cardiac and skeletal muscle as the tissues in which the storage lesion is clinically decisive.
  downstream:
  - target: Cardiomyocyte glycogen storage and progressive hypertrophic remodeling
    description: Cardiomyocyte glycogen storage drives the cardiomegaly and hypertrophic cardiomyopathy that define IOPD.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:12897283
      reference_title: "The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "A progressive cardiac hypertrophy is characteristic for infantile Pompe's disease."
      explanation: Natural-history data establish progressive cardiac hypertrophy as the characteristic infantile consequence of storage.
  - target: Skeletal and respiratory myofiber injury
    description: Storage in skeletal and respiratory myofibers produces the profound hypotonia and respiratory distress of untreated IOPD.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301438
      reference_title: "Pompe Disease."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Untreated individuals with IOPD typically have hypotonia, generalized muscle weakness, feeding difficulties, poor growth, and respiratory distress."
      explanation: GeneReviews attributes the untreated IOPD muscle and respiratory phenotype to the storage lesion.
  - target: Hepatomegaly
    description: >
      Hepatic glycogen storage produces the moderate hepatomegaly of infantile disease.
      The cited cohort attributes it to storage but does not exclude a contribution from
      cardiac decompensation, so the edge is a partial rather than sole explanation.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:12897283
      reference_title: "The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The moderate enlargement of the liver is assumed to result from glycogen storage, but may also result from cardiac decompensation."
      explanation: Attributes the hepatomegaly to glycogen storage while explicitly leaving a cardiac contribution open, which is why this is PARTIAL rather than SUPPORT.
  - target: Failure of productive autophagy and autophagic buildup
    description: Glycogen-laden lysosomes disrupt lysosome-dependent autophagic flux, so autophagic substrate accumulates in muscle.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:38785980
      reference_title: "Failure of Autophagy in Pompe Disease."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "The autophagic pathway is largely responsible for the delivery of cytosolic glycogen to the lysosome where it is degraded to glucose via acid α-glucosidase."
      explanation: Places the autophagic pathway downstream of, and dependent on, the acid alpha-glucosidase step that is lost here.
  - target: Central nervous system glycogen storage and progressive white matter abnormality
    description: >
      Glycogen storage is not confined to muscle; CNS storage becomes clinically
      visible only once ERT allows survival into later childhood.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:29573408
      reference_title: "Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "AIM: To examine the long-term consequences of glycogen storage in the central nervous system (CNS) for classic infantile Pompe disease using enzyme replacement therapy."
      explanation: Frames CNS glycogen storage as the substrate of the long-term brain phenotype in classic infantile disease.
- name: Cardiomyocyte glycogen storage and progressive hypertrophic remodeling
  biological_scale: TISSUE
  description: >
    Massive cardiomyocyte glycogen storage produces cardiomegaly and hypertrophic
    cardiomyopathy that is usually already identifiable in the first weeks of life and
    progresses to left ventricular outflow obstruction and diminished lung volume.
    Glycogen deposition in conduction tissue shortens the PR interval. This node is
    the principal mechanistic difference between IOPD and late-onset Pompe disease,
    which lacks significant cardiac involvement.
  cell_types:
  - preferred_term: Cardiac muscle cell
    term:
      id: CL:0000746
      label: cardiac muscle cell
  biological_processes:
  - preferred_term: Cardiac muscle hypertrophy
    modifier: INCREASED
    term:
      id: GO:0003300
      label: cardiac muscle hypertrophy
  evidence:
  - reference: PMID:20301438
    reference_title: "Pompe Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Cardiomegaly and hypertrophic cardiomyopathy is usually identified in the first weeks of life and progress to left ventricular outflow obstruction and diminished lung volume."
    explanation: Documents the timing and progression of the cardiac lesion specific to IOPD.
  - reference: PMID:12897283
    reference_title: "The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diastolic thickness of the left ventricular posterior wall and cardiac weight at autopsy increase significantly with age."
    explanation: Quantitative natural-history evidence that the cardiac hypertrophy is progressive.
  downstream:
  - target: Hypertrophic cardiomyopathy
    description: Cardiomyocyte storage and hypertrophic remodeling manifest clinically as hypertrophic cardiomyopathy.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301438
      reference_title: "Pompe Disease."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Cardiomegaly and hypertrophic cardiomyopathy is usually identified in the first weeks of life"
      explanation: Directly links the cardiac storage lesion to the hypertrophic cardiomyopathy phenotype.
  - target: Shortened PR interval
    description: Glycogen deposition in the cardiac conduction system shortens the PR interval on ECG.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301438
      reference_title: "Pompe Disease."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Progressive deposition of glycogen results in conduction defects with shortening of the PR interval on EKG."
      explanation: GeneReviews attributes the shortened PR interval directly to glycogen deposition.
  - target: Cardiopulmonary insufficiency of infancy
    description: Progressive cardiac hypertrophy with outflow obstruction is a principal contributor to fatal cardiopulmonary insufficiency.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301438
      reference_title: "Pompe Disease."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "In untreated infants, death commonly occurs in the first two years of life from cardiopulmonary insufficiency."
      explanation: Names cardiopulmonary insufficiency as the mode of death in untreated IOPD.
- name: Skeletal and respiratory myofiber injury
  biological_scale: TISSUE
  description: >
    Lysosomal glycogen storage in skeletal, respiratory, and bulbar muscle injures
    myofibers, producing the floppy-infant presentation: generalized hypotonia,
    severely delayed motor development, feeding difficulty with poor growth, and
    respiratory distress.
  cell_types:
  - preferred_term: Skeletal muscle fiber
    term:
      id: CL:0008002
      label: skeletal muscle fiber
  evidence:
  - reference: PMID:20301438
    reference_title: "Pompe Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Untreated individuals with IOPD typically have hypotonia, generalized muscle weakness, feeding difficulties, poor growth, and respiratory distress."
    explanation: Lists the untreated IOPD muscle phenotype produced by myofiber injury.
  - reference: PMID:12897283
    reference_title: "The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Motor development is severely delayed and major developmental milestones are generally not achieved."
    explanation: Natural-history evidence for the severity of the motor consequence of myofiber injury in IOPD.
  downstream:
  - target: Generalized hypotonia
    description: Myofiber injury produces the profound generalized hypotonia of the floppy infant.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301438
      reference_title: "Pompe Disease."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Untreated individuals with IOPD typically have hypotonia, generalized muscle weakness"
      explanation: GeneReviews links untreated IOPD to hypotonia and generalized muscle weakness.
  - target: Generalized muscle weakness
    description: >
      The same myofiber injury produces generalized skeletal muscle weakness, which
      GeneReviews records as a feature distinct from the accompanying hypotonia.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301438
      reference_title: "Pompe Disease."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Untreated individuals with IOPD typically have hypotonia, generalized muscle weakness"
      explanation: GeneReviews attributes generalized muscle weakness to untreated IOPD, alongside but separate from hypotonia.
  - target: Motor developmental delay
    description: Muscle weakness prevents acquisition of major motor milestones.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:12897283
      reference_title: "The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Motor development is severely delayed and major developmental milestones are generally not achieved."
      explanation: Directly supports severe motor delay as a consequence of the infantile muscle lesion.
  - target: Respiratory insufficiency
    description: Respiratory myofiber injury, compounded by diminished lung volume from cardiomegaly, causes respiratory distress and insufficiency.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301438
      reference_title: "Pompe Disease."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Untreated individuals with IOPD typically have hypotonia, generalized muscle weakness, feeding difficulties, poor growth, and respiratory distress."
      explanation: Respiratory distress is listed among the untreated IOPD manifestations of muscle involvement.
  - target: Feeding difficulties
    description: Bulbar and generalized muscle weakness impair sucking, swallowing, and feeding.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301438
      reference_title: "Pompe Disease."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Untreated individuals with IOPD typically have hypotonia, generalized muscle weakness, feeding difficulties, poor growth, and respiratory distress."
      explanation: Lists feeding difficulties alongside the muscle weakness that produces them.
  - target: Failure to thrive
    description: Growth deviates significantly from normal even once nasogastric tube feeding is started.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:12897283
      reference_title: "The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "For the Dutch patient group, growth deviates significantly from normal despite start of nasogastric tube feeding."
      explanation: Growth failure persisting despite feeding support indicates intermediates beyond reduced intake alone.
  - target: Cardiopulmonary insufficiency of infancy
    description: Respiratory muscle failure combines with the cardiac lesion to produce fatal cardiopulmonary insufficiency.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301438
      reference_title: "Pompe Disease."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "In untreated infants, death commonly occurs in the first two years of life from cardiopulmonary insufficiency."
      explanation: Names cardiopulmonary insufficiency, to which respiratory muscle failure contributes, as the mode of death.
- name: Cardiopulmonary insufficiency of infancy
  biological_scale: ORGANISM
  description: >
    The convergence of hypertrophic cardiomyopathy with outflow obstruction and
    respiratory muscle failure produces cardiopulmonary insufficiency. In the
    pre-treatment natural history, symptoms began at a median age of 1.6 months and
    the median age of death was 6-7.7 months, with only 5-8% of infants surviving
    beyond one year.
  evidence:
  - reference: PMID:12897283
    reference_title: "The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Symptoms start at a median age of 1.6 months in both groups. The median age of death is 7.7 and 6 months, respectively. Five percent of the Dutch patients and 8% of all reported patients survive beyond 1 year of age."
    explanation: Quantifies the untreated natural history of onset and death that this node represents.
  downstream:
  - target: Death in infancy
    description: Untreated, cardiopulmonary insufficiency is fatal in the first one to two years of life.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20301438
      reference_title: "Pompe Disease."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "In untreated infants, death commonly occurs in the first two years of life from cardiopulmonary insufficiency."
      explanation: Directly supports the fatal outcome of untreated IOPD from cardiopulmonary insufficiency.
- name: Absence of immunologically detectable GAA protein (CRIM-negative status)
  biological_scale: MOLECULAR
  description: >
    CRIM (cross-reactive immunologic material) status asks a different question from
    enzyme activity: not whether GAA works, but whether any GAA protein is made at
    all. Patients with two null alleles produce no GAA protein detectable by Western
    blot and are CRIM-negative; patients producing a catalytically inactive protein
    are CRIM-positive. Because a CRIM-negative infant has never been immunologically
    tolerized to GAA, recombinant human GAA is a foreign antigen. Roughly 20-25% of
    classic infantile patients are CRIM-negative, and CRIM status is largely
    predictable from the GAA genotype.
  gene:
    preferred_term: GAA
    description: Null GAA alleles producing no detectable protein define CRIM-negative status.
    modifier: DECREASED
    term:
      id: hgnc:4065
      label: GAA
  evidence:
  - reference: PMID:22252923
    reference_title: "Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "CRIM-negative patients make no GAA protein and develop sustained high antibody titers to ERT that render the treatment ineffective."
    explanation: Defines CRIM-negative status as absence of GAA protein and links it to the antibody response.
  - reference: PMID:19775921
    reference_title: "Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients synthesize a non-functional form of GAA or are unable to form native enzyme."
    explanation: States the CRIM-positive versus CRIM-negative molecular distinction.
  downstream:
  - target: High sustained anti-rhGAA antibody response
    description: >
      Never having been tolerized to endogenous GAA, CRIM-negative infants mount an
      early, high-titer, sustained IgG response to infused recombinant human GAA.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:19775921
      reference_title: "Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "IgG antibodies to rhGAA developed earlier and serotiters were higher and more sustained in the CRIM-negative group."
      explanation: Directly supports the CRIM-negative-to-antibody-response edge with comparative titer data.
    - reference: PMID:20301438
      reference_title: "Pompe Disease."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "individuals who do not produce CRIM (i.e., who are CRIM negative) generally develop high titer anti-rhGAA antibodies during ERT"
      explanation: Management guidance confirms CRIM-negative status predicts a high-titer anti-rhGAA response.
- name: High sustained anti-rhGAA antibody response
  biological_scale: ORGANISM
  description: >
    Sustained high-titer neutralizing IgG against recombinant human GAA blocks the
    therapeutic benefit of enzyme replacement therapy. This is a treatment-conditioned
    mechanism with no counterpart in late-onset disease, and it is the reason CRIM
    status must be determined before the first infusion.
  biological_processes:
  - preferred_term: humoral immune response mediated by circulating immunoglobulin
    modifier: INCREASED
    term:
      id: GO:0002455
      label: humoral immune response mediated by circulating immunoglobulin
  evidence:
  - reference: PMID:22237443
    reference_title: "Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cross-reactive immunologic material negative (CRIM-negative) Pompe patients develop high-titer antibody to the rhGAA and do poorly."
    explanation: Establishes the high-titer antibody response and its adverse clinical consequence.
  downstream:
  - target: Enzyme replacement therapy failure and clinical decline
    description: Neutralizing antibody renders infused rhGAA ineffective, and treated CRIM-negative infants deteriorate.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:19775921
      reference_title: "Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Following 52 weeks of treatment, 6/11 (54.5%) CRIM-negative and 1/21 (4.8%) CRIM-positive patients were deceased or invasively ventilated (p<0.0001)."
      explanation: Quantifies the treatment-failure outcome that follows the CRIM-negative antibody response.
    - reference: PMID:22252923
      reference_title: "Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "CRIM-negative patients make no GAA protein and develop sustained high antibody titers to ERT that render the treatment ineffective."
      explanation: States that the sustained antibody response renders ERT ineffective.
- name: Enzyme replacement therapy failure and clinical decline
  biological_scale: ORGANISM
  description: >
    In the absence of immune tolerance induction, CRIM-negative infants on ERT decline
    despite treatment: cardiac function and gross motor development improve
    significantly less than in CRIM-positive infants, and by roughly 27 months all
    CRIM-negative patients in the original series were dead or invasively ventilated.
  evidence:
  - reference: PMID:19775921
    reference_title: "Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "By age 27.1 months, all CRIM-negative patients and 4/21 (19.0%) CRIM-positive patients were deceased or invasively ventilated."
    explanation: Quantifies the divergent treated outcome by CRIM status.
  - reference: PMID:19775921
    reference_title: "Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cardiac function and gross motor development improved significantly more in the CRIM-positive group."
    explanation: Shows the treatment benefit gap attributable to CRIM status.
- name: Failure of productive autophagy and autophagic buildup
  biological_scale: CELLULAR
  description: >
    Autophagy is lysosome-dependent, so the storage lesion disables it. Autophagic
    vesicles accumulate in type II-rich muscle fibers, disrupting the contractile
    apparatus. Critically for IOPD, the autophagic buildup also acts as a sink for
    infused recombinant enzyme and prevents its efficient delivery to lysosomes -
    a second, non-immune route to poor ERT response that runs in parallel to the
    CRIM-negative antibody arm.
  biological_processes:
  - preferred_term: Autophagy
    modifier: DECREASED
    term:
      id: GO:0006914
      label: autophagy
  cell_types:
  - preferred_term: Skeletal muscle fiber
    term:
      id: CL:0008002
      label: skeletal muscle fiber
  evidence:
  - reference: PMID:20040311
    reference_title: "Autophagy in skeletal muscle: implications for Pompe disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "we present evidence that a failure of productive autophagy in muscle tissue contributes strongly to disease pathology in both patients with Pompe disease and GAA-knockout mice"
    explanation: States that failed productive autophagy contributes to pathology in patients as well as in the knockout mouse.
  downstream:
  - target: Skeletal and respiratory myofiber injury
    description: Accumulated autophagosomes disrupt the contractile apparatus of muscle fibers.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20040311
      reference_title: "Autophagy in skeletal muscle: implications for Pompe disease."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "In the GAA-knockout mouse model, progressive accumulation of autophagic vesicles is restricted to Type II-rich muscle fibers."
      explanation: Localizes the autophagic buildup to the muscle fibers whose injury this edge asserts.
  - target: Enzyme replacement therapy failure and clinical decline
    description: >
      Autophagic buildup sequesters infused recombinant enzyme before it reaches the
      lysosome, degrading ERT response independently of any antibody response.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:20040311
      reference_title: "Autophagy in skeletal muscle: implications for Pompe disease."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Not only does this build-up of autophagosomes disrupt the contractile apparatus in the muscle fibers, it also interferes with enzyme replacement therapy by acting as a sink for the recombinant enzyme and preventing its efficient delivery to the lysosomes."
      explanation: Directly evidences the enzyme-sequestration route from autophagic buildup to reduced ERT efficacy.
- name: Central nervous system glycogen storage and progressive white matter abnormality
  biological_scale: TISSUE
  description: >
    Intravenous rhGAA does not cross the blood-brain barrier, so CNS glycogen storage
    is untreated. As ERT enables survival into later childhood and adulthood, slowly
    progressive symmetric white-matter abnormalities emerge - periventricular white
    matter and centrum semiovale from about age 2, then corpus callosum, capsules and
    subcortical areas after age 8, and brainstem from age 11 - with variable
    neuropsychological consequences. This is an ERT-era emerging phenotype rather than
    part of the classical untreated natural history.
  evidence:
  - reference: PMID:29573408
    reference_title: "Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "From approximately age 2 years onwards, brain MRI showed involvement of the periventricular white matter and centrum semiovale. After 8 years of age, additional white-matter abnormalities occurred in the corpus callosum, internal and external capsule, and subcortical areas. From 11 years of age, white-matter abnormalities were also found in the brainstem."
    explanation: Documents the anatomical progression of white-matter abnormality in treated classic infantile patients.
  downstream:
  - target: Cognitive decline and intellectual disability
    description: White-matter involvement is accompanied by neuropsychological decline in a subset of long-term survivors.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:29573408
      reference_title: "Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "In our long-term survivors treated intravenously with enzyme replacement therapy, we found slowly progressive symmetric white-matter abnormalities. Cognitive development varied from stable and normal to declines towards intellectual disabilities."
      explanation: Directly links progressive white-matter abnormality to the range of cognitive outcomes observed.
phenotypes:
- name: Hypertrophic cardiomyopathy
  category: Cardiovascular
  description: >
    Cardiomegaly with hypertrophic cardiomyopathy, usually identifiable in the first
    weeks of life and progressing to left ventricular outflow obstruction. Its
    presence in an infant with GAA deficiency is what defines classic infantile
    disease rather than late-onset disease.
  frequency: OBLIGATE
  phenotype_term:
    preferred_term: Hypertrophic cardiomyopathy
    term:
      id: HP:0001639
      label: Hypertrophic cardiomyopathy
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:20301438
    reference_title: "Pompe Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Pompe disease can be classified by age of onset, organ involvement, severity, and rate of progression into infantile-onset Pompe disease (IOPD) (i.e., individuals with onset before age 12 months with cardiomyopathy)"
    explanation: Cardiomyopathy is definitional for IOPD, supporting an obligate frequency.
  - reference: PMID:12897283
    reference_title: "The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A progressive cardiac hypertrophy is characteristic for infantile Pompe's disease."
    explanation: Natural-history evidence that cardiac hypertrophy is characteristic and progressive.
- name: Shortened PR interval
  category: Cardiovascular
  description: >
    Glycogen deposition in the cardiac conduction system produces conduction defects
    with a short PR interval on ECG.
  phenotype_term:
    preferred_term: Shortened PR interval
    term:
      id: HP:0005165
      label: Shortened PR interval
  evidence:
  - reference: PMID:20301438
    reference_title: "Pompe Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Progressive deposition of glycogen results in conduction defects with shortening of the PR interval on EKG."
    explanation: Directly documents the shortened PR interval in Pompe disease.
- name: Generalized hypotonia
  category: Neuromuscular
  description: >
    Profound generalized hypotonia and muscle weakness - the classic floppy infant
    presentation of IOPD.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:20301438
    reference_title: "Pompe Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Untreated individuals with IOPD typically have hypotonia, generalized muscle weakness, feeding difficulties, poor growth, and respiratory distress."
    explanation: GeneReviews lists hypotonia as a typical untreated IOPD feature, supporting a very frequent band.
- name: Generalized muscle weakness
  category: Neuromuscular
  description: >
    Generalized skeletal muscle weakness from glycogen-laden myofiber injury. GeneReviews
    names this alongside, and separately from, hypotonia among the typical untreated IOPD
    features, so it is curated as its own phenotype rather than folded into the hypotonia
    entry.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Generalized muscle weakness
    term:
      id: HP:0003324
      label: Generalized muscle weakness
  evidence:
  - reference: PMID:20301438
    reference_title: "Pompe Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Untreated individuals with IOPD typically have hypotonia, generalized muscle weakness, feeding difficulties, poor growth, and respiratory distress."
    explanation: GeneReviews lists generalized muscle weakness as a typical untreated IOPD feature, distinct from the hypotonia named in the same sentence, supporting a very frequent band.
- name: Motor developmental delay
  category: Neuromuscular
  description: >
    Motor development is severely delayed and major motor milestones are generally
    never achieved in untreated infants.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Motor delay
    term:
      id: HP:0001270
      label: Motor delay
  evidence:
  - reference: PMID:12897283
    reference_title: "The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Motor development is severely delayed and major developmental milestones are generally not achieved."
    explanation: Natural-history cohort reports severe motor delay as a general feature, supporting a very frequent band.
- name: Respiratory insufficiency
  category: Respiratory
  description: >
    Respiratory distress and insufficiency from respiratory muscle involvement,
    compounded by diminished lung volume secondary to cardiomegaly.
  phenotype_term:
    preferred_term: Respiratory insufficiency due to muscle weakness
    term:
      id: HP:0002747
      label: Respiratory insufficiency due to muscle weakness
  evidence:
  - reference: PMID:20301438
    reference_title: "Pompe Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Untreated individuals with IOPD typically have hypotonia, generalized muscle weakness, feeding difficulties, poor growth, and respiratory distress."
    explanation: GeneReviews names respiratory distress directly among the typical untreated IOPD features.
  - reference: PMID:20301438
    reference_title: "Pompe Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Cardiomegaly and hypertrophic cardiomyopathy is usually identified in the first weeks of life and progress to left ventricular outflow obstruction and diminished lung volume."
    explanation: Supports the second clause of the description - that the cardiac lesion compounds the respiratory burden by reducing lung volume.
- name: Feeding difficulties
  category: Gastrointestinal
  description: >
    Bulbar and generalized weakness cause feeding difficulty requiring nasogastric or
    gastrostomy feeding.
  phenotype_term:
    preferred_term: Feeding difficulties
    term:
      id: HP:0011968
      label: Feeding difficulties
  evidence:
  - reference: PMID:20301438
    reference_title: "Pompe Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Untreated individuals with IOPD typically have hypotonia, generalized muscle weakness, feeding difficulties, poor growth, and respiratory distress."
    explanation: Lists feeding difficulties among the typical untreated IOPD manifestations.
- name: Failure to thrive
  category: Growth
  description: >
    Growth deviates significantly from normal despite nasogastric tube feeding.
  phenotype_term:
    preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  evidence:
  - reference: PMID:12897283
    reference_title: "The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "For the Dutch patient group, growth deviates significantly from normal despite start of nasogastric tube feeding."
    explanation: Documents growth failure persisting despite feeding support.
- name: Macroglossia
  category: Craniofacial
  description: >
    Glycogen storage in the tongue produces an enlarged tongue, which contributes to
    feeding and airway difficulty and is one of the considerations weighing in favour
    of tracheostomy in infants with severe respiratory insufficiency.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Macroglossia
    term:
      id: HP:0000158
      label: Macroglossia
  evidence:
  - reference: PMID:12897283
    reference_title: "The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "An enlarged tongue was noticed in 45% of the Dutch patients and 29% of the cases from literature."
    explanation: Natural-history cohort quantifies tongue enlargement at 45% in the prospectively examined Dutch series, within the FREQUENT band (79-30%); the 29% literature figure is a retrospective case-note count and is treated as under-ascertainment rather than as a competing estimate.
  - reference: PMID:20301438
    reference_title: "Pompe Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "tracheostomy may be considered in those with macroglossia and severe respiratory insufficiency"
    explanation: GeneReviews management guidance treats macroglossia as a recognised IOPD feature with airway consequences.
- name: Hepatomegaly
  category: Hepatic
  description: >
    Moderate liver enlargement, attributed to hepatic glycogen storage though cardiac
    decompensation may also contribute. No frequency band is asserted: the cohort
    reports 90% in the Dutch series against 29% in the literature cases, a spread too
    wide to map onto a single band.
  phenotype_term:
    preferred_term: Hepatomegaly
    term:
      id: HP:0002240
      label: Hepatomegaly
  evidence:
  - reference: PMID:12897283
    reference_title: "The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The moderate enlargement of the liver is assumed to result from glycogen storage, but may also result from cardiac decompensation."
    explanation: The natural-history cohort reports moderate hepatomegaly and attributes it to glycogen storage with a cardiac contribution.
- name: Elevated creatine kinase
  category: Laboratory
  description: >
    Serum creatine kinase, CK-MB, transaminases, and lactate dehydrogenase are
    typically elevated, with AST, ALT and LDH rising significantly with age.
  phenotype_term:
    preferred_term: Elevated circulating creatine kinase concentration
    term:
      id: HP:0003236
      label: Elevated circulating creatine kinase concentration
  evidence:
  - reference: PMID:12897283
    reference_title: "The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Levels of aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, creatine kinase, or creatine kinase-myocardial band isoenzyme are typically elevated"
    explanation: Directly reports elevated CK and CK-MB in the infantile natural-history cohort.
- name: Death in infancy
  category: Mortality
  description: >
    Untreated, death commonly occurs in the first two years of life from
    cardiopulmonary insufficiency; median age of death in the pre-treatment era was
    6-7.7 months.
  notes: >
    Deliberately left without a phenotype_term. `HP:0001522` (Death in infancy) is
    the exact concept, but it sits under `HP:0040006` (Mortality/Aging) rather than
    `HP:0000118` (Phenotypic abnormality), so it is not a legal PhenotypeTerm value
    in this schema. No mortality term reachable from HP:0000118 expresses it, and no
    term beats a wrong one.
  evidence:
  - reference: PMID:20301438
    reference_title: "Pompe Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In untreated infants, death commonly occurs in the first two years of life from cardiopulmonary insufficiency."
    explanation: States the untreated mortality outcome and its cause.
  - reference: PMID:12897283
    reference_title: "The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The median age of death is 7.7 and 6 months, respectively. Five percent of the Dutch patients and 8% of all reported patients survive beyond 1 year of age."
    explanation: Quantifies median age at death and one-year survival in the untreated natural history.
- name: Abnormal cerebral white matter morphology
  category: Neurological
  description: >
    Slowly progressive symmetric cerebral white-matter abnormalities emerging in
    ERT-treated long-term survivors, beginning in periventricular white matter and
    centrum semiovale around age 2 years.
  phenotype_term:
    preferred_term: Abnormal cerebral white matter morphology
    term:
      id: HP:0002500
      label: Abnormal cerebral white matter morphology
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:29573408
    reference_title: "Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "From approximately age 2 years onwards, brain MRI showed involvement of the periventricular white matter and centrum semiovale."
    explanation: Documents the white-matter abnormality and its age of appearance in treated classic infantile patients.
- name: Cognitive decline and intellectual disability
  category: Neurological
  description: >
    Neuropsychological outcome in ERT-treated long-term survivors ranges from stable
    and normal cognitive development to decline towards intellectual disability.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:29573408
    reference_title: "Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cognitive development ranged from stable and normal to declines that lead to intellectual disabilities."
    explanation: Reports the range of cognitive outcomes, supporting a variably present phenotype.
- name: Sensorineural hearing impairment
  category: Auditory
  description: >
    Sensorineural and/or conductive hearing loss is commonly present in ERT-treated
    long-term survivors of infantile Pompe disease.
  phenotype_term:
    preferred_term: Sensorineural hearing impairment
    term:
      id: HP:0000407
      label: Sensorineural hearing impairment
  evidence:
  - reference: PMID:22538254
    reference_title: "The emerging phenotype of long-term survivors with infantile Pompe disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Commonly present were gross motor weakness, motor speech deficits, sensorineural and/or conductive hearing loss, osteopenia, gastroesophageal reflux, and dysphagia with aspiration risk."
    explanation: Reports hearing loss among the commonly present features of the long-term survivor phenotype.
- name: Osteopenia
  category: Skeletal
  description: >
    Osteopenia is a commonly observed finding in long-term survivors of IOPD on
    enzyme replacement therapy.
  phenotype_term:
    preferred_term: Osteopenia
    term:
      id: HP:0000938
      label: Osteopenia
  evidence:
  - reference: PMID:22538254
    reference_title: "The emerging phenotype of long-term survivors with infantile Pompe disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Residual muscle weakness, hearing loss, risk for arrhythmias, hypernasal speech, dysphagia with risk for aspiration, and osteopenia were commonly observed findings."
    explanation: Lists osteopenia among the commonly observed findings in long-term survivors.
- name: Dysphagia
  category: Gastrointestinal
  description: >
    Dysphagia with aspiration risk is common in ERT-treated long-term survivors.
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
  evidence:
  - reference: PMID:22538254
    reference_title: "The emerging phenotype of long-term survivors with infantile Pompe disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Commonly present were gross motor weakness, motor speech deficits, sensorineural and/or conductive hearing loss, osteopenia, gastroesophageal reflux, and dysphagia with aspiration risk."
    explanation: Reports dysphagia with aspiration risk as commonly present in long-term survivors.
- name: Hypernasal speech
  category: Neuromuscular
  description: >
    Hypernasal speech from velopharyngeal weakness is commonly observed in long-term
    survivors of infantile Pompe disease.
  phenotype_term:
    preferred_term: Hypernasal speech
    term:
      id: HP:0001611
      label: Hypernasal speech
  evidence:
  - reference: PMID:22538254
    reference_title: "The emerging phenotype of long-term survivors with infantile Pompe disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Residual muscle weakness, hearing loss, risk for arrhythmias, hypernasal speech, dysphagia with risk for aspiration, and osteopenia were commonly observed findings."
    explanation: Lists hypernasal speech among commonly observed long-term survivor findings.
genetic:
- name: GAA
  notes: >
    Biallelic fully deleterious GAA variants cause IOPD. The specific pair of alleles
    also determines CRIM status: two alleles that produce no protein at all yield
    CRIM-negative status, whereas alleles producing a catalytically inactive protein
    yield CRIM-positive status. CRIM status can in most cases be predicted from the
    GAA genotype, avoiding a skin biopsy and the weeks of fibroblast culture that
    Western-blot CRIM testing requires - a decisive advantage in a disease where
    treatment delay is measured in weeks.

    Locus and allelic spectrum. GAA lies at 17q25.2-q25.3 and contains 20 exons. The
    allelic spectrum is highly heterogeneous - missense, nonsense, splice-site,
    partial deletions and insertions - and the Pompe disease variant database lists
    well over 900 disease-associated variants, so IOPD genotypes are typically
    private compound heterozygous pairs rather than recurrent founder alleles.

    Copy-number variants are a real diagnostic blind spot. Large deletions are about
    1.5% of known GAA variants and are invisible to exon sequencing, so when
    sequencing returns fewer than two explanatory alleles in a patient with deficient
    enzyme activity, MLPA or another dosage assay should be run before the genetic
    diagnosis is called incomplete.
  gene_term:
    preferred_term: GAA
    term:
      id: hgnc:4065
      label: GAA
  relationship_type: CAUSATIVE
  evidence:
  - reference: PMID:12897283
    reference_title: "The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patients have fully deleterious mutations. Acid alpha-glucosidase activity is severely deficient."
    explanation: Establishes fully deleterious biallelic GAA genotypes as the genetic basis of classic infantile disease.
  - reference: PMID:22252923
    reference_title: "Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We found that, in most cases, CRIM status can be predicted from GAA mutations, potentially circumventing the need for invasive skin biopsy and time wasted in culturing cells in the future."
    explanation: Supports genotype-based prediction of CRIM status from GAA variants.
  - reference: PMID:39482698
    reference_title: "The European reference network for metabolic diseases (MetabERN) clinical pathway recommendations for Pompe disease (acid maltase deficiency, glycogen storage disease type II)."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The GAA gene is localized on chromosome 17 at the 17q25.2–q25.3 locus and contains 20 exons including the 19 coding ones"
    explanation: Establishes the GAA locus and exon structure.
  - reference: PMID:39482698
    reference_title: "The European reference network for metabolic diseases (MetabERN) clinical pathway recommendations for Pompe disease (acid maltase deficiency, glycogen storage disease type II)."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "There is a high allelic heterogeneity/diversity: missense, nonsense, splice-site variants, partial deletions, and insertions have been reported to be causative of the disease."
    explanation: Documents the breadth of GAA variant classes underlying the disease.
  - reference: PMID:39273088
    reference_title: "Mutation Spectrum of GAA Gene in Pompe Disease: Current Knowledge and Results of an Italian Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "For MLPA, large deletions make up only 1.5% of known variants, and the deletion of exon 18 was a common variant in Caucasian patients."
    explanation: Quantifies the large-deletion share of the GAA allelic spectrum, which is the fraction missed by sequencing alone.
  - reference: PMID:39273088
    reference_title: "Mutation Spectrum of GAA Gene in Pompe Disease: Current Knowledge and Results of an Italian Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This method revealed in four subjects the presence of exonic deletions in the GAA gene causative of PD in association with other causative point mutations."
    explanation: Demonstrates that MLPA recovers causative exonic deletions in patients whose sequencing found only one explanatory allele, supporting the dosage-assay recommendation.
biochemical:
- name: Acid alpha-glucosidase enzyme activity
  context: >
    Diagnosis rests on deficient GAA enzyme activity in isolated lymphocytes or mixed
    leukocytes (or fibroblasts/muscle), with classic infantile patients showing
    severely deficient activity, typically less than 1% of the control mean.
  evidence:
  - reference: PMID:20301438
    reference_title: "Pompe Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The diagnosis of Pompe disease is established in a proband who has deficiency of acid alpha-glucosidase (GAA) enzyme activity in isolated lymphocytes or mixed leukocytes"
    explanation: States the diagnostic enzyme assay for Pompe disease.
  - reference: PMID:12897283
    reference_title: "The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Acid alpha-glucosidase activity is severely deficient."
    explanation: Confirms severe enzyme deficiency in the classic infantile cohort.
- name: Urinary glucose tetrasaccharide (Glc4/Hex4)
  context: >
    Urinary glucose tetrasaccharide is a glycogen-burden biomarker used to monitor
    treatment response in IOPD. Together with creatine kinase, low levels correlate
    with favourable response to enzyme replacement therapy, and uGlc4 is the more
    stable of the two.
  evidence:
  - reference: PMID:32373469
    reference_title: "Earlier and higher dosing of alglucosidase alfa improve outcomes in patients with infantile-onset Pompe disease: Evidence from real-world experiences."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Low CK and uGlc4 levels were correlated with favorable response to ERT in IOPD patients, although CK may be more fluctuated than uGlc4."
    explanation: Establishes urinary Glc4 as a monitoring biomarker of ERT response in IOPD.
- name: Anti-rhGAA IgG antibody titer
  context: >
    Serial anti-recombinant-human-GAA IgG titers stratify treatment response.
    CRIM-negative infants develop earlier, higher, and more sustained titers; by
    contrast, long-term survivors of IOPD had low or undetectable anti-alglucosidase
    alfa antibody titers.
  evidence:
  - reference: PMID:19775921
    reference_title: "Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "IgG antibodies to rhGAA developed earlier and serotiters were higher and more sustained in the CRIM-negative group."
    explanation: Reports the antibody-titer difference by CRIM status that makes this a decision-relevant biomarker.
  - reference: PMID:22538254
    reference_title: "The emerging phenotype of long-term survivors with infantile Pompe disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All long-term survivors had low or undetectable anti-alglucosidase alfa antibody titers."
    explanation: Shows the association between low antibody titer and long-term survival on ERT.
treatments:
- name: Enzyme replacement therapy with alglucosidase alfa
  description: >
    Intravenous recombinant human GAA is the disease-specific therapy for IOPD.
    Initiated before age six months and before the need for ventilatory assistance, it
    improves survival and ventilator-independent survival, reduces cardiac mass, and
    substantially improves motor skill acquisition. High-dose ERT started immediately
    on a newborn-screening diagnosis gives the best reported outcomes.
  therapeutic_modality: PROTEIN_REPLACEMENT
  treatment_term:
    preferred_term: enzyme replacement therapy
    term:
      id: NCIT:C16221
      label: Protein Replacement Therapy
    therapeutic_agent:
    - preferred_term: alglucosidase alfa
      term:
        id: NCIT:C65221
        label: Alglucosidase Alfa
  target_phenotypes:
  - preferred_term: Hypertrophic cardiomyopathy
    term:
      id: HP:0001639
      label: Hypertrophic cardiomyopathy
  - preferred_term: Motor delay
    term:
      id: HP:0001270
      label: Motor delay
  target_mechanisms:
  - target: Lysosomal glycogen accumulation
    treatment_effect: INHIBITS
    description: Infused recombinant human GAA supplies the missing lysosomal enzyme and clears stored glycogen.
    evidence:
    - reference: PMID:20301438
      reference_title: "Pompe Disease."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "In those in whom enzyme replacement therapy (ERT) is initiated before age six months and before the need for ventilatory assistance, a majority have improved survival, improved ventilator-independent survival, reduced cardiac mass, and significantly improved acquisition of motor skills compared to untreated individuals."
      explanation: Reduced cardiac mass and improved survival evidence the reversal of the storage lesion by ERT.
  evidence:
  - reference: PMID:17151339
    reference_title: "Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All patients (100%) survived to 18 months of age. A Cox proportional hazards analysis demonstrated that treatment reduced the risk of death by 99%, reduced the risk of death or invasive ventilation by 92%, and reduced the risk of death or any type of ventilation by 88%, as compared to an untreated historical control group."
    explanation: Pivotal trial quantifies the survival benefit of rhGAA in infantile-onset disease.
  - reference: PMID:32373469
    reference_title: "Earlier and higher dosing of alglucosidase alfa improve outcomes in patients with infantile-onset Pompe disease: Evidence from real-world experiences."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "High-dose ERT instituted immediately at newborn screening seems to give the best outcome, and a dosage increase is necessary upon - or, even better, before - a rise in biomarker levels."
    explanation: Real-world cohort supports early, high-dose ERT initiation at newborn screening.
  - reference: PMID:32373469
    reference_title: "Earlier and higher dosing of alglucosidase alfa improve outcomes in patients with infantile-onset Pompe disease: Evidence from real-world experiences."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In patients with classical IOPD diagnosed through newborn screening, those late in ERT initiation (p = .006) or late in high-dosage ERT initiation (p = .044) had a higher risk of motor decline."
    explanation: Quantifies the penalty of delayed ERT initiation on motor outcome in classic IOPD.
- name: Avalglucosidase alfa
  description: >
    A next-generation recombinant human GAA with enhanced mannose-6-phosphate receptor
    binding. In the Mini-COMET phase 2 trial, children with IOPD who had declined or
    responded suboptimally to alglucosidase alfa were switched to avalglucosidase
    alfa, with persistent normalization of left ventricular mass z score, falling
    disease-burden biomarkers, and improved or stable motor function through 97 weeks.
  therapeutic_modality: PROTEIN_REPLACEMENT
  treatment_term:
    preferred_term: enzyme replacement therapy
    term:
      id: NCIT:C16221
      label: Protein Replacement Therapy
    therapeutic_agent:
    - preferred_term: avalglucosidase alfa
      term:
        id: NCIT:C169795
        label: Avalglucosidase Alfa
  target_phenotypes:
  - preferred_term: Hypertrophic cardiomyopathy
    term:
      id: HP:0001639
      label: Hypertrophic cardiomyopathy
  target_mechanisms:
  - target: Lysosomal glycogen accumulation
    treatment_effect: INHIBITS
    description: Avalglucosidase alfa delivers recombinant GAA to the lysosome via enhanced mannose-6-phosphate receptor uptake.
    evidence:
    - reference: PMID:40449831
      reference_title: "The Mini-COMET Clinical Trial: Safety and Efficacy of Avalglucosidase Alfa after 97 Weeks of Treatment in Children with Infantile-Onset Pompe Disease Previously Treated with Alglucosidase Alfa."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Compared with baseline, biomarkers of Pompe disease burden decreased, and motor function improved or stabilized."
      explanation: Falling disease-burden biomarkers evidence reduction of the glycogen storage lesion.
  evidence:
  - reference: PMID:40449831
    reference_title: "The Mini-COMET Clinical Trial: Safety and Efficacy of Avalglucosidase Alfa after 97 Weeks of Treatment in Children with Infantile-Onset Pompe Disease Previously Treated with Alglucosidase Alfa."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Echocardiography revealed persistent left ventricular mass z score normalization. Compared with baseline, biomarkers of Pompe disease burden decreased, and motor function improved or stabilized."
    explanation: Mini-COMET reports cardiac, biomarker, and motor outcomes for avalglucosidase alfa in IOPD.
- name: Immune tolerance induction with rituximab and methotrexate
  description: >
    Because CRIM-negative infants neutralize rhGAA, immune tolerance induction is
    given prophylactically at ERT initiation, or therapeutically once antibodies
    appear. Rituximab (anti-CD20 B-cell depletion) plus methotrexate, with or without
    intravenous immunoglobulin, eliminated established anti-rhGAA antibody and
    conferred durable tolerance off all immune therapy with B-cell recovery. It is
    most effective before an entrenched high-titer response develops, which is why
    CRIM status should be known before the first infusion.
  therapeutic_modality: MONOCLONAL_ANTIBODY
  treatment_term:
    preferred_term: immune tolerance induction
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: rituximab
      term:
        id: NCIT:C1702
        label: Rituximab
    - preferred_term: methotrexate
      term:
        id: NCIT:C642
        label: Methotrexate
  target_mechanisms:
  - target: High sustained anti-rhGAA antibody response
    treatment_effect: INHIBITS
    description: B-cell depletion plus antimetabolite immunomodulation prevents or eliminates the neutralizing anti-rhGAA IgG response.
    evidence:
    - reference: PMID:22237443
      reference_title: "Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "In both patients treated therapeutically, anti-rhGAA was eliminated after 3 and 19 months. All four patients are immune tolerant to rhGAA, off immune therapy, showing B-cell recovery while continuing to receive ERT"
      explanation: Directly evidences elimination of the antibody response and durable tolerance.
  evidence:
  - reference: PMID:22237443
    reference_title: "Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All patients show clinical response to ERT, in stark contrast to the rapid deterioration of their nontolerized CRIM-negative counterparts."
    explanation: Contrasts tolerized with non-tolerized CRIM-negative infants, supporting the clinical value of tolerance induction.
  - reference: PMID:20301438
    reference_title: "Pompe Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "individuals who do not produce CRIM (i.e., who are CRIM negative) generally develop high titer anti-rhGAA antibodies during ERT and require modified therapy protocols using immunomodulation early in the treatment course, optimally before the first infusion."
    explanation: Management guidance specifying immunomodulation for CRIM-negative infants, optimally before the first infusion.
- name: Intravenous immunoglobulin adjunct
  description: >
    Intravenous gammaglobulin was used alongside rituximab and methotrexate in the
    therapeutic (post-antibody) tolerance-induction regimen; the prophylactic regimen
    given at ERT initiation used a short rituximab-plus-methotrexate course
    essentially without IVIG.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: immunoglobulin therapy
    term:
      id: NCIT:C62710
      label: Immunoglobulin Therapy
  target_mechanisms:
  - target: High sustained anti-rhGAA antibody response
    treatment_effect: INHIBITS
    description: IVIG was part of the therapeutic tolerance-induction combination that eliminated established anti-rhGAA antibody.
    evidence:
    - reference: PMID:22237443
      reference_title: "Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The combination of rituximab with methotrexate ± intravenous gammaglobulins (IVIG) is an option for tolerance induction of CRIM-negative Pompe to ERT when instituted in the naïve setting or following antibody development."
      explanation: Names IVIG as a component of the tolerance-induction combination.
  evidence:
  - reference: PMID:22237443
    reference_title: "Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Two CRIM-negative patients with preexisting anti-GAA antibodies were treated therapeutically with rituximab, methotrexate, and gammaglobulins."
    explanation: Describes the therapeutic regimen in which IVIG was used.
- name: Respiratory support
  description: >
    Respiratory support for respiratory insufficiency may include CPAP and BiPAP;
    tracheostomy may be considered in infants with macroglossia and severe respiratory
    insufficiency. Invasive ventilator-free survival is the primary outcome measure in
    IOPD trials.
  therapeutic_modality: DEVICE
  treatment_term:
    preferred_term: artificial respiration
    term:
      id: NCIT:C70909
      label: Mechanical Ventilation
  target_phenotypes:
  - preferred_term: Respiratory insufficiency due to muscle weakness
    term:
      id: HP:0002747
      label: Respiratory insufficiency due to muscle weakness
  evidence:
  - reference: PMID:20301438
    reference_title: "Pompe Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Respiratory support for those with respiratory insufficiency may include CPAP and BiPAP; tracheostomy may be considered in those with macroglossia and severe respiratory insufficiency."
    explanation: Specifies the respiratory support options in Pompe disease management.
- name: Feeding therapy and gastrostomy
  description: >
    Feeding therapy with consideration of a gastrostomy tube is recommended for
    infants with feeding and nutritional difficulties, though growth may still deviate
    from normal despite tube feeding.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Dietary management
    term:
      id: NCIT:C15447
      label: Dietary Intervention
  target_phenotypes:
  - preferred_term: Feeding difficulties
    term:
      id: HP:0011968
      label: Feeding difficulties
  - preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  evidence:
  - reference: PMID:20301438
    reference_title: "Pompe Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Feeding therapy and consideration of a gastrostomy tube is recommended for those who have feeding/nutritional difficulties."
    explanation: States the recommended feeding intervention.
- name: Cardiac management with Pompe-specific drug precautions
  description: >
    Medical intervention for cardiomyopathy must be individualized because standard
    cardiac drugs may be contraindicated at certain disease stages; digoxin,
    inotropes, diuretics, and afterload-reducing agents may worsen left ventricular
    outflow obstruction.
  treatment_term:
    preferred_term: supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
  target_phenotypes:
  - preferred_term: Hypertrophic cardiomyopathy
    term:
      id: HP:0001639
      label: Hypertrophic cardiomyopathy
  evidence:
  - reference: PMID:20301438
    reference_title: "Pompe Disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The use of digoxin, ionotropes, diuretics, and afterload-reducing agents may worsen left ventricular outflow"
    explanation: Lists cardiac drugs that may worsen outflow obstruction in Pompe disease.
  - reference: PMID:39482698
    reference_title: "The European reference network for metabolic diseases (MetabERN) clinical pathway recommendations for Pompe disease (acid maltase deficiency, glycogen storage disease type II)."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ECG and Echocardiogram should be performed at diagnosis, and at regular intervals (every 12 months or more frequently, depending on patients’ conditions, in the presence of cardiomyopathy)."
    explanation: The MetabERN European clinical pathway recommendations set the cardiac surveillance schedule that accompanies this individualized cardiac management.
clinical_trials:
- name: NCT03019406
  phase: PHASE_II
  status: ACTIVE_NOT_RECRUITING
  description: >
    Mini-COMET: a phase 2, open-label, ascending-dose, three-cohort study of
    avalglucosidase alfa in children with infantile-onset Pompe disease who were
    declining or responding suboptimally to prior alglucosidase alfa.
  target_phenotypes:
  - preferred_term: Hypertrophic cardiomyopathy
    term:
      id: HP:0001639
      label: Hypertrophic cardiomyopathy
  evidence:
  - reference: PMID:40449831
    reference_title: "The Mini-COMET Clinical Trial: Safety and Efficacy of Avalglucosidase Alfa after 97 Weeks of Treatment in Children with Infantile-Onset Pompe Disease Previously Treated with Alglucosidase Alfa."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The Mini-COMET clinical trial, a phase 2, open-label, ascending-dose, 3-cohort study, has a 25-week primary analysis period (PAP) and an extension treatment period (ETP)."
    explanation: Describes the design of the registered Mini-COMET trial in infantile-onset Pompe disease.
- name: NCT04910776
  phase: PHASE_III
  status: ACTIVE_NOT_RECRUITING
  description: >
    Baby-COMET: a phase 3, open-label, single-group study of avalglucosidase alfa in
    treatment-naive pediatric participants with infantile-onset Pompe disease. It is
    the first-line counterpart of Mini-COMET, which enrolled only children already
    declining on alglucosidase alfa, and so speaks to whether avalglucosidase alfa is
    an alternative to alglucosidase alfa at diagnosis rather than a salvage option.
  target_phenotypes:
  - preferred_term: Hypertrophic cardiomyopathy
    term:
      id: HP:0001639
      label: Hypertrophic cardiomyopathy
  - preferred_term: Generalized muscle weakness
    term:
      id: HP:0003324
      label: Generalized muscle weakness
  evidence:
  - reference: clinicaltrials:NCT04910776
    reference_title: "An Open-label, Multinational, Multicenter, Intravenous Infusion Study of the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Avalglucosidase Alfa in Treatment naïve Pediatric Participants With Infantile-Onset Pompe Disease (IOPD)"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This is a single group, treatment, Phase 3, open-label study to assess efficacy, safety, pharmacokinetic (PK), pharmacodynamics (PD) of avalglucosidase alfa in treatment-naïve male and female participants with IOPD."
    explanation: The registry record establishes the phase, design, and treatment-naive IOPD population of the trial.
discussions:
- discussion_id: gap_iopd_cns_glycogen_white_matter
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Central nervous system glycogen storage and progressive white matter abnormality
  prompt: >-
    Does the progressive cerebral white-matter abnormality of ERT-treated IOPD
    survivors reflect ongoing CNS glycogen storage that intravenous rhGAA cannot
    reach, and would a brain-penetrant therapy prevent it?
  rationale: >-
    The cohort study establishes the white-matter phenotype and its temporal
    progression but does not demonstrate the storage-to-white-matter mechanism
    directly, nor is there interventional evidence that reducing CNS glycogen
    alters the neuropsychological trajectory. The authors explicitly frame the
    brain as an additional target for next-generation therapy rather than a
    solved mechanism.
  proposed_experiments:
  - experiment_id: exp_iopd_cns_glycogen_imaging
    name: Longitudinal CNS glycogen and white-matter imaging in treated IOPD
    description: >-
      Correlate a CNS glycogen-burden measure with serial quantitative
      white-matter MRI and neuropsychological testing in a multi-centre treated
      IOPD cohort, and compare against recipients of brain-directed enzyme
      delivery when such therapy becomes available.
  evidence:
  - reference: PMID:29573408
    reference_title: "Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Therefore, we advise follow-up programs are expanded to capture CNS involvement in larger, international patient cohorts, to incorporate our findings in the counselling of parents before the start of treatment, and to include the brain as an additional target in the development of next-generation therapeutic strategies for classic infantile Pompe disease.
    explanation: The authors frame CNS involvement as an open target rather than a resolved mechanism.

animal_models:
- name: GAA-knockout mouse
  species: Mouse
  genotype: Gaa knockout (GAA-null)
  publication: PMID:20040311
  description: >
    The GAA-knockout mouse reproduces the lysosomal glycogen storage lesion and was
    the system in which the autophagic-buildup arm of Pompe muscle pathology, and its
    interference with enzyme replacement therapy, was established.
  evidence:
  - reference: PMID:20040311
    reference_title: "Autophagy in skeletal muscle: implications for Pompe disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Not only does this build-up of autophagosomes disrupt the contractile apparatus in the muscle fibers, it also interferes with enzyme replacement therapy by acting as a sink for the recombinant enzyme and preventing its efficient delivery to the lysosomes."
    explanation: Reports the knockout-mouse finding that makes this model informative here - autophagic buildup both damages the contractile apparatus and sequesters infused recombinant enzyme.
  modeled_mechanisms:
  - target: Failure of productive autophagy and autophagic buildup
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >
      Progressive accumulation of autophagic vesicles in type II-rich fibers, with
      sequestration of infused recombinant enzyme.
    limitations: >-
      The autophagic buildup in this model is restricted to type II-rich fibers, and
      mouse and human skeletal muscle differ in fiber-type composition, so the
      proportion of muscle affected does not transfer directly. The model is also not
      specific to the infantile form: it models GAA deficiency, not the age of onset
      or cardiac severity that defines IOPD, and it says nothing about CRIM status,
      the other determinant of ERT response in infants.
    readouts:
    - name: Autophagic vesicle accumulation in type II-rich muscle fibers
      target: Failure of productive autophagy and autophagic buildup
      direction: INCREASED
      interpretation: Histological correlate of the autophagic-buildup node in this model.
      evidence:
      - reference: PMID:20040311
        reference_title: "Autophagy in skeletal muscle: implications for Pompe disease."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "In the GAA-knockout mouse model, progressive accumulation of autophagic vesicles is restricted to Type II-rich muscle fibers."
        explanation: Reports the measurement and its direction in the knockout mouse.
    evidence:
    - reference: PMID:20040311
      reference_title: "Autophagy in skeletal muscle: implications for Pompe disease."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "we present evidence that a failure of productive autophagy in muscle tissue contributes strongly to disease pathology in both patients with Pompe disease and GAA-knockout mice"
      explanation: Supports treating the knockout mouse as informative for the autophagy node in human disease.
notes: >
  Scope. This entry curates MONDO:0017694, the classic infantile-onset form of
  glycogen storage disease due to acid maltase deficiency. It is a child of
  Pompe Disease (MONDO:0009290), which remains the umbrella entry covering the
  whole GAA-deficiency continuum; the late-onset form is a separate concept
  (MONDO:0018485). Shared mechanism - GAA deficiency, lysosomal glycogen
  accumulation - is stated here because dismech entries are self-contained rather
  than inheriting, but the content that justifies a separate entry is the
  IOPD-specific material: near-total enzyme deficiency, the obligate cardiac
  phenotype, the untreated infantile natural history, the CRIM-status/anti-rhGAA
  antibody axis with its immune-tolerance-induction therapy, and the ERT-era
  long-term-survivor phenotype including CNS white-matter disease.

  Terminology caution. IOPD is defined by onset before 12 months WITH
  cardiomyopathy. Onset before 12 months WITHOUT cardiomyopathy is classified by
  GeneReviews as late-onset disease, so "infantile" in the literature does not
  always mean IOPD in this sense; some sources call the latter atypical or
  non-classical infantile disease. Snippets quoted here were checked to be about
  the classic cardiac infantile form.

  CRIM status is not the same as enzyme activity. Enzyme activity asks whether GAA
  works; CRIM asks whether any GAA protein exists. Both CRIM-positive and
  CRIM-negative IOPD patients have essentially no enzyme activity - the difference
  is immunological, and it is what determines whether enzyme replacement therapy
  works.
references:
- reference: PMID:12897283
  title: "The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature."
- reference: PMID:19775921
  title: "Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants."
- reference: PMID:22252923
  title: "Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience."
- reference: PMID:22237443
  title: "Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease."
- reference: PMID:22538254
  title: "The emerging phenotype of long-term survivors with infantile Pompe disease."
- reference: PMID:29573408
  title: "Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain."
- reference: PMID:32373469
  title: "Earlier and higher dosing of alglucosidase alfa improve outcomes in patients with infantile-onset Pompe disease: Evidence from real-world experiences."
- reference: PMID:40449831
  title: "The Mini-COMET Clinical Trial: Safety and Efficacy of Avalglucosidase Alfa after 97 Weeks of Treatment in Children with Infantile-Onset Pompe Disease Previously Treated with Alglucosidase Alfa."
- reference: PMID:20040311
  title: "Autophagy in skeletal muscle: implications for Pompe disease."
- reference: PMID:38785980
  title: "Failure of Autophagy in Pompe Disease."
- reference: PMID:20301438
  title: "Pompe Disease."
  tags:
    - GeneReviews
- reference: PMID:17151339
  title: "Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease."
- reference: PMID:39482698
  title: "The European reference network for metabolic diseases (MetabERN) clinical pathway recommendations for Pompe disease (acid maltase deficiency, glycogen storage disease type II)."
- reference: PMID:39273088
  title: "Mutation Spectrum of GAA Gene in Pompe Disease: Current Knowledge and Results of an Italian Study."
📚

References & Deep Research

References

14
PMID:12897283
The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature.
No top-level findings curated for this source.
PMID:19775921
Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants.
No top-level findings curated for this source.
PMID:22252923
Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience.
No top-level findings curated for this source.
PMID:22237443
Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease.
No top-level findings curated for this source.
PMID:22538254
The emerging phenotype of long-term survivors with infantile Pompe disease.
No top-level findings curated for this source.
PMID:29573408
Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain.
No top-level findings curated for this source.
PMID:32373469
Earlier and higher dosing of alglucosidase alfa improve outcomes in patients with infantile-onset Pompe disease: Evidence from real-world experiences.
No top-level findings curated for this source.
PMID:40449831
The Mini-COMET Clinical Trial: Safety and Efficacy of Avalglucosidase Alfa after 97 Weeks of Treatment in Children with Infantile-Onset Pompe Disease Previously Treated with Alglucosidase Alfa.
No top-level findings curated for this source.
PMID:20040311
Autophagy in skeletal muscle: implications for Pompe disease.
No top-level findings curated for this source.
PMID:38785980
Failure of Autophagy in Pompe Disease.
No top-level findings curated for this source.
PMID:20301438
Pompe Disease.
No top-level findings curated for this source.
PMID:17151339
Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease.
No top-level findings curated for this source.
PMID:39482698
The European reference network for metabolic diseases (MetabERN) clinical pathway recommendations for Pompe disease (acid maltase deficiency, glycogen storage disease type II).
No top-level findings curated for this source.
PMID:39273088
Mutation Spectrum of GAA Gene in Pompe Disease: Current Knowledge and Results of an Italian Study.
No top-level findings curated for this source.

Deep Research

1
Falcon ▸
Infantile-Onset Pompe Disease: Disease-Characteristics Research Report
Edison Scientific Literature 31 citations 2026-08-18T21:27:33.610110

Infantile-Onset Pompe Disease: Disease-Characteristics Research Report

Executive summary

Infantile-onset Pompe disease (IOPD) is the severe, early-onset end of the autosomal-recessive GAA deficiency spectrum. Near-absent lysosomal acid α-glucosidase activity causes glycogen accumulation, lysosomal and autophagic dysfunction, and rapidly progressive cardiomyopathy, generalized hypotonia, bulbar weakness, and respiratory failure. Without disease-specific treatment, classic IOPD is usually fatal during the first year of life. Enzyme-replacement therapy (ERT), newborn screening, and CRIM-guided immune-tolerance induction have transformed survival, although long-term survivors retain substantial skeletal-muscle, bulbar, auditory, respiratory, and possibly central-nervous-system morbidity. The most authoritative recent clinical synthesis is the November 2024 MetabERN pathway (DOI: 10.1186/s13023-024-03373-w). (parenti2024theeuropeanreference pages 2-4, moschetti2024mutationspectrumof pages 1-2, prater2012theemergingphenotype pages 1-3)

The following table provides a compact knowledge-base summary; the narrative below expands and qualifies each field.

Domain Summary Key ontology mappings Quantitative details Evidence source(s)
Definition / IDs Infantile-onset Pompe disease (IOPD; classic/atypical infantile acid maltase deficiency) is the severe early-onset form of glycogen storage disease type II, a lysosomal storage disorder caused by acid alpha-glucosidase deficiency with glycogen accumulation, especially in cardiac and skeletal muscle. Disease-level information here is from aggregated literature/guidelines, not individual EHRs. MONDO: glycogen storage disease II = MONDO:0009290; Orphanet: 365; MeSH/ICD not confidently extracted here; UBERON: heart UBERON:0000948, skeletal muscle tissue UBERON:0001134, diaphragm UBERON:0001103, lysosome (GO CC) GO:0005764 MetabERN notes atypical infantile presentation may occur after 6 months but within first 2 years; untreated classic IOPD is typically fatal within the first year. Parenti et al., 2024; Moschetti et al., 2024 (parenti2024theeuropeanreference pages 2-4, moschetti2024mutationspectrumof pages 1-2)
Cause and inheritance Primary cause is biallelic pathogenic variants in GAA causing markedly reduced/absent lysosomal acid alpha-glucosidase activity. Inheritance is autosomal recessive. CRIM status is a major treatment-response modifier; CRIM-negative patients lack endogenous GAA protein and are at higher risk of anti-ERT immune responses. Environmental causes are not established. Gene: GAA; GO BP: glycogen catabolic process GO:0005980, autophagy GO:0006914; CL: skeletal muscle cell CL:0000187, cardiomyocyte CL:0000746 MetabERN cites 648 documented disease-associated variants (as of Dec 2020); a 2024 review reports >911 disease-associated GAA variants; about one-third of infantile Pompe patients are CRIM-negative. Parenti et al., 2024; Moschetti et al., 2024; Open Targets GAA-disease association (parenti2024theeuropeanreference pages 2-4, moschetti2024mutationspectrumof pages 1-2, OpenTargets Search: Pompe disease-GAA)
Hallmark phenotypes Core manifestations: hypertrophic cardiomyopathy, generalized hypotonia/floppy infant phenotype, respiratory insufficiency, feeding difficulty, motor delay/regression, macroglossia, hepatomegaly; long-term survivors may show persistent gross motor weakness, dysphagia/aspiration risk, motor speech deficits, hearing loss, osteopenia, and GERD. HPO: cardiomyopathy HP:0001638, hypertrophic cardiomyopathy HP:0001639, hypotonia HP:0001252, respiratory insufficiency HP:0002093, hepatomegaly HP:0002240, macroglossia HP:0000158, dysphagia HP:0002015, hearing impairment HP:0000365, delayed gross motor development HP:0002194 In a long-term survivor series, 11 IOPD survivors had median age 8.0 y (range 5.4–12.0); 7/11 were independently ambulatory. Prater et al., 2012; Parenti et al., 2024; Moschetti et al., 2024 (prater2012theemergingphenotype pages 1-3, parenti2024theeuropeanreference pages 2-4, moschetti2024mutationspectrumof pages 2-3)
Mechanism / pathophysiology Upstream defect: GAA loss causes lysosomal glycogen accumulation. Downstream cascade: lysosomal enlargement, rupture/leakage of glycogen into cytoplasm, impaired autophagic flux, secondary accumulation of autophagic material, mitochondrial dysfunction and oxidative stress, culminating in cardiac, skeletal, smooth-muscle, and neural dysfunction. CNS involvement is increasingly recognized but incompletely corrected by standard ERT. GO BP: lysosomal transport GO:0007041 (broadly relevant), autophagy GO:0006914, response to oxidative stress GO:0006979; GO CC: lysosome GO:0005764; CL: motor neuron CL:0000100, endothelial cell CL:0000115 Gene-therapy review notes cross-correction may require only about 1–10% of normal enzyme activity for effective substrate clearance in LSD paradigms. Uribe-Carretero et al., 2024; Moschetti et al., 2024; Leon-Astudillo et al., 2023 (uribecarretero2024lysosomaldysfunctionconnecting pages 14-16, moschetti2024mutationspectrumof pages 2-3, leonastudillo2023currentavenuesof pages 11-12)
Diagnosis Typical workflow: first-line enzyme testing on dried blood spot (DBS), then confirmatory enzyme assay in leukocytes/fibroblasts and GAA sequencing; CRIM status assessment is important before/at ERT initiation. Supportive tests commonly include CK and disease biomarkers such as urinary/plasma glucose tetrasaccharide (Glc4/Hex4), plus ECG/echocardiography and respiratory evaluation. HPO/lab-related: elevated creatine kinase not mapped here with confidence; UBERON: blood UBERON:0000178, skin fibroblast culture not ontologized here In one older long-term cohort, diagnostic enzyme activity in fibroblasts/muscle was <1% of control mean; an Italian diagnostic cohort screened 2934 subjects and identified 39 symptomatic PD patients with two causative mutations plus 22 GVUS cases. Moschetti et al., 2024; Prater et al., 2012 (moschetti2024mutationspectrumof pages 2-3, prater2012theemergingphenotype pages 1-3)
Epidemiology Pompe disease frequency varies by population and ascertainment method; newborn screening (NBS) generally yields higher observed birth prevalence than historical clinical diagnosis. Certain founder/pseudodeficiency backgrounds complicate interpretation in some populations. MONDO:0009290; no additional population ontology asserted MetabERN: overall incidence about 1:40,000–1:146,000; in NBS countries 1:8,684–1:23,596; Taiwan about 1:17,000; French Guiana about 1:2,000. Population-genetic study: global GAA carrier frequency 1.3%; common variant c.-32-13T>G AF 0.0033 globally (mostly relevant to LOPD/carrier screening, not specific to IOPD). Parenti et al., 2024; Choi et al., 2024 (parenti2024theeuropeanreference pages 2-4, OpenTargets Search: Pompe disease-GAA)
Current treatment Standard of care is enzyme replacement therapy (ERT) with alglucosidase alfa initiated as early as possible; prophylactic immune tolerance induction (ITI) is used particularly for CRIM-negative IOPD. Multidisciplinary supportive care includes cardiology, pulmonology/ventilation, nutrition/swallow management, PT/OT/speech therapy, and monitoring of antibody titers and biomarkers. Avalglucosidase alfa is an emerging/next-generation option under pediatric study rather than established universal standard for IOPD. NCIT terms not asserted confidently; GO/CL/UBERON as above for affected systems Long-term survivor cohort: biweekly ERT at cumulative doses 20–40 mg/kg; all survivors had cardiac improvement and low/undetectable antibody titers. Avalglucosidase pediatric trial records: Mini-COMET NCT03019406, planned enrollment 22; Baby-COMET NCT04910776, enrollment 17. Prater et al., 2012; Unnisa et al., 2022; ClinicalTrials.gov records (prater2012theemergingphenotype pages 1-3, unnisa2022genetherapydevelopments pages 2-3, OpenTargets Search: Pompe disease-GAA)
Prognosis Natural history is rapidly progressive and often lethal in infancy without therapy. ERT has markedly improved survival and ventilator-free survival, but residual disease remains common in long-term survivors, especially musculoskeletal, bulbar, auditory, and possibly CNS complications. Prognosis is modified by CRIM status, age at treatment start, antibody response, and likely residual enzyme activity/genotype. HPO: progressive muscle weakness HP:0003323 (broad), respiratory failure HP:0002878 Pre-ERT prognosis commonly death by age <2 y; Moschetti review states classic untreated fatality often within 1 year. In the survivor cohort, 11 long-term survivors were alive at school age with persistent morbidity. Moschetti et al., 2024; Prater et al., 2012; Kishnani et al., 2007 referenced in retrieved literature (moschetti2024mutationspectrumof pages 1-2, prater2012theemergingphenotype pages 1-3)
Screening / prevention Secondary prevention is most important: newborn screening enables presymptomatic or very early treatment and CRIM-guided planning. Primary prevention of disease occurrence is not available; genetic counseling, carrier testing, cascade testing, prenatal diagnosis, and preimplantation testing are relevant for at-risk families. No extra ontology confidently asserted Northeast Italy screened about 250,000 neonates: 126 positives (0.051%), 51 confirmed affected, 40% PPV, overall incidence 1:4,874 across 4 LSDs; 3 IOPD infants were immediately treated. China NBGS cohort screened 22,687 newborns with 6.0% carriers, 0.13% initial positives, and 15 presymptomatic LSD diagnoses overall. Gragnaniello et al., 2023; Wang et al., 2025 (gragnaniello2023lightandshadows pages 1-2, wang2025effectofnewborn pages 1-2)
Emerging therapies / models Experimental directions include next-generation ERT (avalglucosidase alfa), AAV- and lentiviral-based gene therapy, liver- and muscle-directed delivery, CNS-targeted/intrathecal approaches, substrate reduction (e.g., GYS1 inhibition), and even in utero ERT proof-of-concept. Key models include Gaa−/− mouse, naturally occurring Japanese quail disease, and large-animal models. Model systems not ontology-mapped here; GO: glycogen biosynthetic process GO:0005978 relevant to substrate reduction concept In utero ERT case: single treated fetus with normal cardiac and age-appropriate motor function at 13 months. Muscle-directed gene therapy review cites AAV8 liver-directed study in 4 LOPD subjects and ongoing pediatric avalglucosidase trial NCT03019406. Animal-model review summarized 42 GSD animal models total, including 26 genetically modified mouse models and 15 naturally occurring models; Pompe-relevant naturally occurring models include quail and large animals. Cohen et al., 2022; Leon-Astudillo et al., 2023; Almodóvar-Payá et al., 2020; Ullman et al., 2024 (preclinical Pompe mouse substrate reduction) (cohen2022inuteroenzymereplacement pages 12-14, leonastudillo2023currentavenuesof pages 11-12, unnisa2022genetherapydevelopments pages 2-3, OpenTargets Search: Pompe disease-GAA)

Table: This table condenses key disease-knowledge-base fields for infantile-onset Pompe disease, including identifiers, genetics, phenotypes, mechanisms, diagnostics, epidemiology, treatment, and emerging translational research. It is designed as a compact reference with ontology suggestions, quantitative details, and cited evidence sources.

1. Disease information

Definition and classification

Pompe disease—glycogen storage disease type II—is a lysosomal glycogen-storage disorder caused by deficiency of acid α-glucosidase. Classic IOPD generally presents in the first weeks or months with hypertrophic cardiomyopathy and profound generalized hypotonia. “Non-classic” or atypical infantile Pompe disease presents in infancy, sometimes after six months but within approximately two years, and may have less prominent cardiomyopathy. This report treats IOPD as a clinical subtype of the broader Pompe disease entity rather than a genetically separate disorder. (parenti2024theeuropeanreference pages 2-4, moschetti2024mutationspectrumof pages 2-3, moschetti2024mutationspectrumof pages 1-2)

Identifiers and synonyms

  • MONDO: MONDO:0009290, glycogen storage disease II. The available source maps this broad entity rather than a distinct IOPD-only MONDO record.
  • OMIM: #232300, glycogen storage disease II/Pompe disease; causal gene GAA, OMIM *606800.
  • Orphanet: ORPHA:365, glycogen storage disease due to acid maltase deficiency.
  • ICD-10-CM: E74.02, Pompe disease.
  • ICD-11: generally classified under glycogen-storage diseases/inborn errors of carbohydrate metabolism; local coding-browser verification is advised before database ingestion.
  • MeSH: Glycogen Storage Disease Type II.
  • Synonyms: Pompe disease, acid maltase deficiency, acid α-glucosidase deficiency, glycogenosis type II, GSD II, lysosomal glycogen-storage disease, infantile acid maltase deficiency, classic infantile Pompe disease.

Open Targets identifies GAA as the dominant disease-associated target for MONDO:0009290 and ORPHA:365, supported by human genetic literature including PMIDs 11071489, 16917947, 20080426, 18429042, 16782080, and 14695532. Other genes returned by broad association searches are not established causes of Pompe disease and should not be entered as causal genes. (OpenTargets Search: Pompe disease-GAA)

Evidence granularity

The information summarized here is principally aggregated disease-level evidence from guidelines, cohorts, trials, and reviews. It is not an extraction from individual electronic health records. Case reports, such as prenatal ERT, are explicitly labeled as single-patient evidence.

2. Etiology, risk, protection, and gene–environment interaction

Causal factor

The sole established primary cause is germline biallelic pathogenic or likely pathogenic variation in GAA, located on chromosome 17q25.3. GAA encodes lysosomal acid α-glucosidase, which hydrolyzes α-1,4- and α-1,6-linked glycogen to glucose. Severe alleles producing minimal or no residual enzyme generally cause IOPD; genotype–phenotype correlation remains imperfect because residual activity, protein production, immune response, and treatment timing modify expression. Variant classes include missense, nonsense, frameshift, canonical and noncanonical splice variants, small insertions/deletions, and exon-level or larger rearrangements. A 2024 review reported more than 911 disease-associated variants, whereas MetabERN cited 648 documented variants as of December 2020, illustrating continued database growth rather than a true discrepancy. (parenti2024theeuropeanreference pages 2-4, moschetti2024mutationspectrumof pages 1-2)

Genetic risk and modifiers

  • Autosomal-recessive genotype: two disease-causing alleles are necessary; heterozygous carriers are generally asymptomatic.
  • Residual GAA activity: near-absence favors classic IOPD; greater residual activity tends toward later onset.
  • CRIM status: approximately one-third of infantile patients are reported as CRIM-negative. Absence of endogenous immunologically detectable GAA increases the risk of high, sustained anti-rhGAA antibodies and poor ERT response. Some CRIM-positive patients also develop clinically important antibodies. (parenti2024theeuropeanreference pages 2-4, moschetti2024mutationspectrumof pages 2-3)
  • Treatment-related modifiers: younger age and lower disease burden at ERT initiation, adequate dosing, and prevention of deleterious antibodies improve outcomes. These are modifiers of prognosis rather than risk of inheriting disease.
  • Founder/population effects: marked geographic variation, including very high frequency in French Guiana, indicates founder effects. Specific pathogenic and pseudodeficiency alleles also vary by ancestry.

No modifier gene has been validated sufficiently for routine clinical prediction. The weak Open Targets association with TTN should not be interpreted as evidence that TTN modifies or causes IOPD. (OpenTargets Search: Pompe disease-GAA)

Environmental, infectious, lifestyle, and protective factors

There is no credible evidence that toxins, infection, smoking, diet, alcohol, radiation, or occupation cause IOPD. Sex is not a causal risk factor, and both sexes should be affected approximately equally. Family history and consanguinity increase the probability of inheriting two familial alleles but do not alter the molecular mechanism.

No established genetic “protective allele” prevents disease in a person carrying two severe pathogenic alleles. Relative protection is conferred by residual-function genotypes and—clinically—presymptomatic diagnosis, immediate ERT, immune-tolerance induction when indicated, vaccination/infection prevention, respiratory support, safe nutrition, and rehabilitation. There is no established disease-specific gene–environment interaction. Intercurrent respiratory infection, fasting, malnutrition, or prolonged immobility may unmask or worsen limited cardiopulmonary reserve but are downstream stressors, not causes.

3. Phenotypes

Core phenotype map

Phenotype Type, onset, course, and frequency Functional/QoL impact Suggested HPO
Hypertrophic cardiomyopathy/cardiomegaly Clinical sign; usually early infancy; severe and progressive untreated; characteristic of classic IOPD Heart failure, arrhythmia risk, feeding intolerance, reduced endurance HP:0001639; HP:0001640
Generalized hypotonia Sign; neonatal/early infantile; severe, progressive “Floppy infant,” impaired antigravity movement and self-care HP:0001252; generalized hypotonia HP:0001290
Progressive muscle weakness Sign; axial, proximal, respiratory and bulbar muscles; nearly universal clinically Delayed milestones, loss of mobility, dependence for transfers HP:0003323; HP:0003701
Respiratory muscle weakness/insufficiency Sign; infancy; progressive; respiratory infection often precipitates decompensation Sleep-disordered breathing, ventilatory dependence, mortality HP:0002093; HP:0002878; HP:0002791
Feeding difficulty, dysphagia, weak suck Symptom/sign; early infancy; common Aspiration, prolonged meals, tube feeding, poor growth HP:0011968; HP:0002015; HP:0008872
Macroglossia Physical manifestation; infancy; characteristic but variable Airway and feeding burden HP:0000158
Hepatomegaly Sign, usually from glycogen and/or cardiac congestion; common Abdominal distension; usually not primary hepatic failure HP:0002240
Motor delay/regression Developmental manifestation; infancy; severe untreated Loss/failure of sitting, standing, walking HP:0001270; HP:0002194
Elevated CK/AST/ALT/LDH Laboratory abnormalities; variable Supports muscle injury but is not diagnostic HP:0003236 for elevated CK
ECG abnormalities Short PR interval, high voltages, ventricular hypertrophy patterns Arrhythmia surveillance and anesthesia implications HP:0005165; more specific ECG terms as observed
Hearing impairment Particularly evident among ERT-era survivors; sensorineural, conductive, or mixed Communication and educational effects; hearing aids may be needed HP:0000365; HP:0000407
Dysarthria/motor-speech disorder Long-term survivor phenotype Reduced intelligibility and social participation HP:0001260
Osteopenia/low bone density Long-term complication influenced by weakness and reduced loading Fracture and mobility risk HP:0000938
GERD Common supportive-care problem Pain, aspiration and feeding burden HP:0002020

The 2024 variant review describes severe progressive hypotonia, hypertrophic cardiomyopathy, respiratory insufficiency, and delayed or regressing motor development. The authors’ abstract-level framing is that IOPD includes a severe “floppy baby” phenotype. (moschetti2024mutationspectrumof pages 2-3)

In a human clinical series of 11 ERT-treated long-term survivors, median age was 8.0 years (range 5.4–12.0), seven were independently ambulatory, and all showed sustained cardiac improvement. Nevertheless, motor weakness, speech impairment, hearing loss, dysphagia/aspiration risk, osteopenia, and GERD remained. Thus ERT changes—not eliminates—the phenotype. (prater2012theemergingphenotype pages 1-3)

Disease-specific pediatric quality-of-life estimates remain less standardized than motor, respiratory, and survival endpoints. The practical burden includes repeated lifelong infusions, ventilatory or feeding support, impaired mobility and communication, frequent specialist visits, caregiver time, and uncertainty about long-term neurologic outcomes.

4. Genetic and molecular information

Gene and protein

  • Gene: GAA; HGNC:4065; Ensembl ENSG00000171298.
  • Protein: lysosomal acid α-glucosidase/acid maltase; synthesized as a precursor, mannose-6-phosphate–targeted to lysosomes, and proteolytically matured.
  • Origin: constitutional/germline. Somatic mutation is not a recognized cause.
  • Functional effect: overwhelmingly loss of function—reduced synthesis, misfolding, defective trafficking or processing, instability, or reduced catalytic activity. Gain-of-function and dominant-negative mechanisms are not established.

Variant interpretation and testing cautions

Pathogenicity should be assigned using ACMG/AMP criteria integrating allele frequency, segregation, phenotype, enzyme activity, RNA/protein consequences, functional studies, and curated databases. Pseudodeficiency alleles can lower in-vitro activity against assay substrates without clinical Pompe disease, particularly complicating newborn screening. A VUS plus low DBS activity is not sufficient by itself for diagnosis.

The 2024 Italian study screened 2,934 symptomatic subjects, finding 39 with low enzyme activity and two causative GAA variants and 22 with variants of uncertain significance. This demonstrates the need to couple biochemistry with complete genetic interpretation. (moschetti2024mutationspectrumof pages 2-3)

Population allele frequencies are variant-specific. Severe IOPD alleles are individually rare. In a 2024 gnomAD-based analysis across recessive neuromuscular diseases, GAA had the highest estimated carrier frequency, 1.3%, and c.-32-13T>G had global allele frequency 0.0033; that splice variant is primarily associated with late-onset disease and should not be used as an IOPD-specific frequency estimate.

CRIM and epigenetics

CRIM is a protein-expression phenotype, not an independent gene. It may be predicted from well-characterized variants or measured by Western blot/protein methods. CRIM-negative status strongly informs immunomodulation. No reproducible disease-defining DNA-methylation, histone, or chromatin signature is currently used clinically. There is likewise no characteristic chromosomal aneuploidy or translocation; exon-level GAA deletions/duplications are sequence-level structural variants and should be sought when sequencing finds fewer than two explanatory alleles.

5. Environmental information

IOPD is not infectious, toxic, occupational, or lifestyle-mediated. No pathogen is causal or transmissible, and there is no zoonotic risk. Respiratory infections can cause acute deterioration because respiratory muscle reserve and airway clearance are poor. Sedentary behavior is generally a consequence of weakness; carefully prescribed activity may preserve function, whereas exhaustion or eccentric overload should be avoided. Adequate calories and protein, aspiration prevention, vaccination, and prompt infection treatment are supportive—not curative—interventions.

6. Mechanism and pathophysiology

Causal chain

  1. Upstream genetic defect: biallelic GAA loss-of-function.
  2. Biochemical defect: deficient lysosomal hydrolysis of glycogen to glucose.
  3. Primary storage: glycogen accumulates in lysosomes of cardiomyocytes, skeletal and smooth muscle cells, vascular cells, and neural populations.
  4. Organelle injury: lysosomes enlarge; membrane integrity and trafficking deteriorate. Glycogen and cellular debris may escape into cytoplasm.
  5. Autophagic pathology: impaired autophagosome–lysosome processing produces autophagic buildup that disrupts sarcomeres and can impede uptake/trafficking of infused enzyme.
  6. Secondary injury: mitochondrial dysfunction, altered calcium/energy homeostasis, oxidative stress, inflammatory signaling, apoptosis and failed regeneration amplify damage.
  7. Tissue manifestations: cardiomyocyte enlargement causes hypertrophic cardiomyopathy; myofiber destruction causes hypotonia and weakness; diaphragmatic and motor-neuron involvement causes respiratory failure; bulbar and hypoglossal-system involvement contributes to dysphagia and speech/airway dysfunction.

The 2024 MetabERN synthesis explicitly identifies glycogen/autophagic accumulation, mitochondrial dysfunction, and oxidative stress. The 2024 mutation review describes progression from small glycogen-filled lysosomes to enlargement and rupture with cytoplasmic glycogen and muscle damage. (parenti2024theeuropeanreference pages 2-4, moschetti2024mutationspectrumof pages 2-3)

Relevant ontology suggestions

  • GO biological process: glycogen catabolic process GO:0005980; autophagy GO:0006914; lysosomal transport GO:0007041; response to oxidative stress GO:0006979; muscle contraction GO:0006936.
  • GO cellular component: lysosome GO:0005764; autophagosome GO:0005776; mitochondrion GO:0005739; sarcomere GO:0030017.
  • Cell Ontology: skeletal muscle cell CL:0000187; cardiomyocyte CL:0000746; smooth muscle cell CL:0000192; motor neuron CL:0000100; endothelial cell CL:0000115; macrophage CL:0000235.

Immunity

Immune involvement is mainly iatrogenic immunogenicity to recombinant GAA rather than autoimmunity. CRIM-negative patients recognize rhGAA as foreign and are particularly susceptible to high sustained antibodies, reduced enzyme exposure, and poor clinical response. Prophylactic B-cell/T-cell–directed immune-tolerance induction is therefore a central part of precision care. Approximately one-third of infantile patients may be CRIM-negative. (parenti2024theeuropeanreference pages 2-4, moschetti2024mutationspectrumof pages 2-3)

Molecular profiling and advanced technologies

Human IOPD-specific single-cell, spatial, proteomic, lipidomic, and metabolomic datasets remain limited. A 2024 single-nucleus/spatial-transcriptomic study was in late-onset Pompe muscle, not IOPD; it found increased slow/regenerative fibers and macrophages, early reduction of glycolytic genes, increased lipid/amino-acid metabolism, increased autophagy genes, reduced ribosomal/mitochondrial programs, defective oxidative phosphorylation, and inflammation/apoptosis in vacuolated fibers. These pathways are biologically relevant but should not be entered as directly proven IOPD signatures without validation.

Preclinical multi-omics provides stronger mechanistic than diagnostic evidence. In Pompe mice, selective GYS1 inhibition corrected biochemical, metabolomic, and transcriptomic abnormalities as glycogen was lowered. No omics assay is currently a routine diagnostic standard for IOPD.

7. Anatomical structures affected

Organ and system level

  • Primary: heart, skeletal muscle, diaphragm and other respiratory muscles, bulbar/oropharyngeal musculature.
  • Additional: smooth muscle, peripheral and central motor systems, vasculature, liver, hearing apparatus, bone secondarily through immobility/nutrition.
  • Systems: cardiovascular, neuromuscular, respiratory, gastrointestinal/nutritional, auditory, skeletal, and increasingly recognized CNS involvement.

Tissue, cell, and subcellular localization

Cardiomyocytes and skeletal myofibers are the major clinically damaged cells; motor neurons, smooth-muscle cells, endothelial cells and pericytes can also store glycogen. The key subcellular compartment is the lysosome, with downstream autophagosomal, mitochondrial and sarcomeric disruption. The 2024 review specifically identifies smooth and skeletal muscle, endothelial cells, motor neurons, and heart as involved. (moschetti2024mutationspectrumof pages 2-3)

Suggested UBERON terms include heart UBERON:0000948, skeletal muscle tissue UBERON:0001134, diaphragm UBERON:0001103, tongue UBERON:0001723, liver UBERON:0002107, spinal cord UBERON:0002240, and brainstem UBERON:0002298. Manifestations are generally bilateral/systemic rather than lateralized.

8. Temporal development

Classic IOPD is congenital in molecular origin and likely begins prenatally, although obvious clinical signs usually emerge over the first weeks or months. Onset is chronic-progressive rather than episodic. Untreated stages can be conceptualized as: early hypotonia/feeding difficulty and cardiac hypertrophy; progressive motor failure and respiratory infections; then ventilator dependence, heart/respiratory failure, and death. There is no spontaneous remission.

The critical therapeutic window is before substantial irreversible muscle, motor-neuron, and cardiac injury. Newborn screening and family-based prenatal diagnosis shift treatment toward this window. The prenatal ERT case supports prenatal substrate accumulation: the investigators opened their abstract with, “organ damage starts in utero.” (cohen2022inuteroenzymereplacement pages 12-14)

ERT induces rapid cardiac improvement more reliably than complete skeletal-muscle recovery. Disease remains lifelong and progressive residual pathology may emerge even when cardiomyopathy resolves.

9. Inheritance and population

Inheritance counseling

Inheritance is autosomal recessive. For two confirmed carrier parents, each pregnancy has a 25% probability of an affected child, 50% probability of an unaffected carrier, and 25% probability of an unaffected non-carrier. Penetrance for two severe IOPD-causing alleles is expected to be high, but age and severity vary. There is no genetic anticipation. Germline mosaicism is theoretically possible but is not a major established contributor; parental testing is still important when variants appear de novo. Consanguinity raises the chance that both parents carry the same rare allele.

Epidemiology

MetabERN reports historical overall incidence estimates of approximately 1:40,000–1:146,000, compared with approximately 1:8,684–1:23,596 in newborn-screened populations. Reported birth prevalence is around 1:17,000 in Taiwan and as high as 1:2,000 in French Guiana. These figures usually encompass all Pompe phenotypes and should not be mislabeled as IOPD-only incidence. (parenti2024theeuropeanreference pages 2-4)

The 2023 Northeast Italy program screened about 250,000 newborns for four lysosomal disorders. There were 126 screen positives (0.051%), 51 confirmed affected, and a 40% positive predictive value across all four disorders; three infants with IOPD were identified and immediately treated. The combined four-disorder incidence was 1:4,874, not Pompe-specific incidence. (gragnaniello2023lightandshadows pages 1-2)

There is no consistent sex bias. Geographic and ethnic differences reflect allele frequencies, founder effects, pseudodeficiency alleles, screening design, and access to diagnosis.

10. Diagnostics

Recommended diagnostic sequence

  1. Urgent biochemical screening: GAA activity in dried blood spot, preferably with an inhibitor/assay system that minimizes interference from maltase-glucoamylase.
  2. Confirmation: repeat enzyme assay in leukocytes, lymphocytes, cultured fibroblasts, or another validated tissue.
  3. Molecular confirmation: full GAA sequencing with deletion/duplication analysis; familial variant testing where known.
  4. CRIM determination/prediction: from established genotype or protein testing; do not delay lifesaving ERT while awaiting prolonged work-up.
  5. Baseline staging: ECG, echocardiography, cardiology review; oxygenation, blood gas where indicated, respiratory-muscle and sleep assessment; swallow/feeding evaluation; hearing assessment; motor/developmental evaluation.

The 2024 Italian review describes sequential DBS/fibroblast/muscle enzyme testing followed by complete GAA sequencing for low or borderline activity. (moschetti2024mutationspectrumof pages 2-3)

Biomarkers and clinical tests

  • Enzyme: deficient acid α-glucosidase activity is the principal biochemical marker.
  • Muscle injury: CK, AST, ALT and LDH are often elevated but nonspecific.
  • Storage: urinary or plasma glucose tetrasaccharide, Glc4/Hex4, supports diagnosis and longitudinal response; values can be affected by age and other glycogen disorders.
  • Cardiac: ECG may show short PR and high voltages; echocardiography quantifies hypertrophy and function.
  • Respiratory: pulse oximetry alone may miss hypoventilation; capnography/blood gases, sleep study, cough strength and age-appropriate pulmonary testing are useful.
  • Electrophysiology: EMG may show an irritable myopathy but is not required in a biochemically/genetically clear infant.
  • Biopsy: vacuolated, PAS-positive glycogen-rich myofibers and lysosomal glycogen by electron microscopy; usually unnecessary when enzyme and molecular results are definitive.

Genomic modalities

Single-gene sequencing plus copy-number analysis is usually sufficient. A neuromuscular/cardiomyopathy panel, WES, or WGS is useful when the presentation is atypical or initial testing is negative; WGS may detect deep-intronic and structural variants. RNA sequencing can resolve suspected splice variants but is adjunctive. CMA, karyotype, FISH, mitochondrial DNA testing, and repeat-expansion testing are not routine unless another diagnosis is suspected.

Differential diagnosis

Key alternatives include spinal muscular atrophy, congenital muscular dystrophies/myopathies, Danon disease, PRKAG2 cardiomyopathy, mitochondrial disease, fatty-acid oxidation disorders, other glycogenoses, congenital disorders of glycosylation, sepsis, hypothyroidism, and structural/congenital cardiomyopathy. Cardiomyopathy plus marked hypotonia, macroglossia, elevated muscle enzymes, and very low GAA strongly favors IOPD.

Screening

Newborn screening measures GAA activity in DBS, often followed by second-tier biomarkers and rapid molecular testing. False positives arise from sample quality, pseudodeficiency, heterozygosity, and VUS; detection of late-onset genotypes creates counseling and follow-up challenges. The Italian program’s authors concluded that screening was feasible and effective but emphasized false positives and uncertain/late-onset findings. (gragnaniello2023lightandshadows pages 1-2)

11. Outcome and prognosis

Untreated course

Classic untreated IOPD is rapidly fatal, generally from cardiorespiratory failure during the first year; older natural-history series commonly place death or invasive ventilation by one to two years. The 2024 review characterizes untreated outcome as invariably fatal within one year. (moschetti2024mutationspectrumof pages 1-2)

Treated course

ERT substantially improves overall and ventilator-free survival, reverses cardiac hypertrophy, and permits motor milestone acquisition in many infants, especially when started presymptomatically. However, there is no reliable single five- or ten-year survival estimate applicable across genotype, CRIM status, start age, dose, and immune-management era.

In the 11-patient survivor cohort, all had cardiac improvement and seven walked independently, but residual weakness, speech and swallowing problems, hearing loss, osteopenia, and GERD were frequent. This is strong evidence that cardiac response does not equal multisystem cure. (prater2012theemergingphenotype pages 1-3)

Prognostic factors and biomarkers

Favorable factors are diagnosis through newborn/family screening, ERT before irreversible injury, CRIM positivity or successful immune tolerance, low anti-drug antibody titers, lower baseline cardiac/motor burden, and sustained biochemical response. Adverse factors include CRIM negativity without prophylactic immunomodulation, high sustained antibodies, delayed ERT, severe baseline ventilation/feeding dependence, and advanced muscle pathology. Serial LV mass, motor milestones, ventilation status, CK and Glc4/Hex4 are useful response/prognostic measures, but none is a fully validated standalone surrogate for long-term neurologic outcome.

12. Treatment

Disease-specific pharmacotherapy

Alglucosidase alfa is recombinant human GAA and the foundational standard of care. It is internalized through the cation-independent mannose-6-phosphate receptor and delivered to lysosomes. A conventional labeled regimen is 20 mg/kg intravenously every two weeks, although expert centers often use higher exposure—commonly 40 mg/kg weekly or every two weeks—in IOPD based on disease severity and emerging outcome data. Exact dosing must follow jurisdictional labeling and specialist protocols. Long-term survivors in one cohort received cumulative biweekly doses of 20–40 mg/kg. (prater2012theemergingphenotype pages 1-3)

Avalglucosidase alfa is glycoengineered with additional bis-mannose-6-phosphate moieties to enhance cellular uptake. It is a next-generation ERT with established use in Pompe disease in some jurisdictions and active pediatric/IOPD evaluation. Preclinical Pompe mice achieved stronger skeletal-muscle glycogen reduction and comparable heart/diaphragm clearance at fourfold lower dose than standard rhGAA. (unnisa2022genetherapydevelopments pages 2-3)

Suggested NCIT concepts are enzyme replacement therapy, alglucosidase alfa, avalglucosidase alfa, intravenous infusion, immunosuppressive therapy, physical therapy, occupational therapy, speech therapy, mechanical ventilation, and enteral nutrition; identifiers should be validated against the current NCIT release before ingestion.

Immune-tolerance induction

CRIM status should be established or predicted urgently. CRIM-negative infants generally receive prophylactic immune-tolerance induction at ERT initiation, commonly rituximab, methotrexate, and intravenous immunoglobulin in specialist protocols. Some high-risk CRIM-positive infants may also be considered. Anti-rhGAA IgG titers and clinical/biochemical response require serial monitoring. Established high sustained titers are harder to eradicate than to prevent.

Supportive and rehabilitative care

  • Cardiac monitoring and cautious management of heart failure/arrhythmia; anesthesia requires a metabolic-cardiac team.
  • Airway clearance, assisted cough, noninvasive ventilation, escalation to invasive ventilation when necessary, sleep evaluation, and prompt infection treatment.
  • Swallow studies, texture adaptation, caloric/protein support, reflux treatment, and nasogastric or gastrostomy feeding when aspiration or growth failure warrants.
  • Individualized PT/OT emphasizing positioning, contracture prevention, low-to-moderate submaximal activity, orthoses, mobility aids, and avoidance of overwork weakness.
  • Speech-language therapy for feeding, dysarthria and augmentative communication.
  • Hearing, vision, bone health, dental, developmental, educational, and psychosocial surveillance.

Surgery is not disease-modifying. Gastrostomy, tracheostomy, orthopedic procedures, and vascular access are supportive interventions selected case by case.

Adverse effects

ERT can cause infusion-associated reactions, anaphylaxis, pyrexia, rash and antibody formation. Cardiorespiratory instability during infusion is especially consequential in infants with advanced hypertrophic cardiomyopathy. Immunomodulation adds infection, cytopenia and vaccine-response risks.

Trials and experimental therapy

  • Mini-COMET, NCT03019406: phase 2 pediatric IOPD study of avalglucosidase alfa in previously alglucosidase-treated patients; 22 participants; active, not recruiting in the retrieved registry record.
  • Baby-COMET, NCT04910776: phase 3 avalglucosidase study in treatment-naïve IOPD; 17 participants; active, not recruiting.
  • NCT06666413: phase 4 post-approval avalglucosidase study in Chinese IOPD; 13 planned participants; recruiting in the retrieved record.
  • NCT05017402: observational study of higher-dose alglucosidase, 36 planned participants.

Gene-therapy platforms include in-vivo AAV liver-, muscle-, and CNS-directed expression and ex-vivo lentiviral HSPC therapy. Potential advantages are continuous enzyme secretion, cross-correction, immune tolerance, and CNS access; limitations include vector immunity, dose-related toxicity, pediatric growth-related dilution, redosing barriers, manufacturing, and uncertain durability. A 2023 review concluded: “Gene therapy for the treatment of patients with Pompe disease is feasible,” while emphasizing vector production, immune reactions and redosing. (leonastudillo2023currentavenuesof pages 11-12)

Prenatal ERT remains experimental. In a single CRIM-negative fetus treated in utero and then postnatally, cardiac function and age-appropriate motor development were normal at 13 months, biomarkers were normal, and feeding/growth were satisfactory. Placental pathology showed marked reduction of glycogen storage. This is proof of concept, not efficacy evidence from a controlled trial. DOI: 10.1056/NEJMoa2200587, published December 2022. (cohen2022inuteroenzymereplacement pages 12-14)

Substrate reduction: selective muscle glycogen synthase-1 inhibition is preclinical. MZ-101 reduced skeletal-muscle glycogen comparably to ERT in Pompe mice, while combination treatment was additive and normalized muscle glycogen; translation to infants remains unproven.

13. Prevention

Primary prevention through lifestyle or vaccination is not possible because the disorder is inherited. Relevant prevention levels are:

  • Primary genetic prevention: preconception carrier testing in at-risk relatives/populations, genetic counseling, IVF with preimplantation genetic testing, and prenatal diagnosis by chorionic-villus sampling or amniocentesis for known familial variants.
  • Secondary prevention: newborn screening, rapid confirmatory testing, presymptomatic ERT, and CRIM-guided immune tolerance. This is the most effective strategy for preventing irreversible organ damage.
  • Tertiary prevention: vaccination, respiratory-infection precautions, airway clearance, aspiration prevention, adequate nutrition, contracture/osteopenia prevention, hearing support, and multidisciplinary surveillance.

Cascade testing should be offered to siblings and extended relatives. There is no disease-specific vaccine or prophylactic medication that prevents inheritance. Standard immunizations are important, but timing may need adjustment around rituximab or other immunosuppression.

14. Other species and natural disease

Pompe-like GAA deficiency occurs naturally in several species, including Japanese quail and reported cattle, dogs, cats, and sheep. Orthologous GAA is conserved, and the shared pathology is lysosomal glycogen accumulation with skeletal/cardiac muscle disease. Species-specific severity, neuroanatomy, immune responses and lifespan limit direct extrapolation.

A 2020 review catalogued 42 glycogen-storage-disease models overall: 26 genetically modified mouse models, 15 naturally occurring models spanning quail, cats, dogs, sheep, cattle and horses, and one genetically modified zebrafish. These totals cover all GSDs, not Pompe alone; Japanese quail is the best-known spontaneous Pompe model. There is no zoonotic transmission or cross-species contagion.

Suggested taxonomy entries include Homo sapiens NCBI Taxon 9606, Mus musculus 10090, Coturnix japonica 93934, Canis lupus familiaris 9615, Bos taurus 9913, Felis catus 9685, and Ovis aries 9940. Breed-specific VBO mapping requires variant-specific veterinary reports.

15. Model organisms and experimental systems

Gaa-knockout mice

The Gaa−/− mouse is the principal mammalian model. It reproduces systemic enzyme deficiency, glycogen accumulation, autophagic pathology, skeletal weakness and variable cardiac/respiratory disease. It is extensively used for ERT, AAV, immune-tolerance, glycogen-synthase inhibition and CNS-targeting studies. Limitations include differences from human infant cardiomyopathy, scale, immune responses, vector tropism, and lifespan.

Intrathecal or spinal AAV studies in Pompe mice have produced long-term neurologic/cardiac correction and increased ventilation. Chemogenetic activation of hypoglossal motoneurons has been used to dissect neural contributions to swallowing, speech-related and sleep-disordered-breathing phenotypes. These are model-organism findings, not clinical efficacy evidence. (leonastudillo2023currentavenuesof pages 11-12)

Large animals and nonhuman primates

Large animals better model systemic delivery, anatomy and dose scaling but are scarce. In AT845 studies, systemic muscle-directed AAV increased GAA, cleared glycogen and improved function in Gaa−/− mice. High-dose treatment in cynomolgus macaques caused anti-human-GAA immune inflammation and cardiac abnormalities, whereas macaque GAA did not, illustrating species-specific xenogeneic immunogenicity and limitations of toxicity prediction.

Cellular models

Patient fibroblasts, immortalized myoblasts, primary myotubes, CRISPR-engineered cells, and patient-derived iPSC cardiomyocytes/skeletal myocytes model enzyme processing, lysosomal storage, autophagy, cardiomyocyte hypertrophy, variant function and therapeutic rescue. Limitations include immature iPSC phenotypes, absent whole-organ mechanics/innervation, and incomplete modeling of systemic immunity and cross-correction. Muscle organoids and neuromuscular co-cultures are promising but not yet validated diagnostic platforms.

Recent developments and expert interpretation, 2023–2024

  1. Standardized European pathway: the November 2024 MetabERN recommendations integrate diagnosis, ERT, immune management, respiratory/nutritional support and follow-up using AGREE II/GRADE methodology. This is the strongest recent authoritative care framework. DOI: 10.1186/s13023-024-03373-w. (parenti2024theeuropeanreference pages 2-4, parenti2024theeuropeanreference pages 22-23)
  2. Variant expansion: the August 2024 GAA review documents continued allelic growth and reinforces paired biochemical/genetic diagnosis and CRIM-informed care. DOI: 10.3390/ijms25179139. (moschetti2024mutationspectrumof pages 2-3, moschetti2024mutationspectrumof pages 1-2)
  3. Real-world newborn screening: Northeast Italy’s eight-year report showed operational feasibility at approximately 250,000 births, with three IOPD infants immediately treated, while quantifying false-positive/VUS challenges. Published December 2023; DOI: 10.3390/ijns10010003. (gragnaniello2023lightandshadows pages 1-2)
  4. Gene therapy maturation: 2023–2024 reviews conclude that AAV and lentiviral platforms are clinically plausible but remain constrained by immunity, redosing, durability and CNS delivery. DOI: 10.1097/WCO.0000000000001187. (leonastudillo2023currentavenuesof pages 11-12, unnisa2022genetherapydevelopments pages 18-19)
  5. Mechanism-directed combination therapy: 2024 preclinical work on selective GYS1 inhibition supports reducing glycogen synthesis alongside replacement of its degradation pathway. This is mechanistically compelling but not yet human IOPD therapy.

Evidence limitations

IOPD is ultra-rare, so many treatment and long-term phenotype data derive from small, nonrandomized cohorts, historical controls, registry studies, or case reports. Incidence estimates often combine infantile and late-onset Pompe disease. Omics studies are disproportionately based on late-onset muscle or animal models. Exact phenotype frequencies are therefore often qualitative rather than population percentages. Direct quotations above are limited to text available from retrieved abstracts; absence of a PMID in this report means it was not reliably present in the retrieved record, not that the article lacks one.

References

  1. (parenti2024theeuropeanreference pages 2-4): Giancarlo Parenti, Simona Fecarotta, Marianna Alagia, Federica Attaianese, Alessandra Verde, Antonietta Tarallo, Vincenza Gragnaniello, Athanasia Ziagaki, Maria Jose’ Guimaraes, Patricio Aguiar, Andreas Hahn, Olga Azevedo, Maria Alice Donati, Beata Kiec-Wilk, Maurizio Scarpa, Nadine A. M. E. van der Beek, Mireja Del Toro Riera, Dominique P. Germain, Hidde Huidekoper, Johanna M. P. van den Hout, Ans T. van der Ploeg, Ivo Baric, Spyros Batzios, Nadia Belmatoug, Andrea Bordugo, Annet M. Bosch, Anais Brassier, Alberto Burlina, David Cassiman, Brigitte Chabrol, Efstathia Chronopoulou, Maria Luz Couce-Pico, Niklas Darin, Anibh M. Das, Francois G. Debray, Patrick Deegan, Luisa M. de Abreu Freire Diogo Matos, Javier De Las Heras Montero, Maja Di Rocco, Dries Dobbelaere, Francois Eyskens, Ana Ferreira, Ana M. Gaspar, Serena Gasperini, Antonio González-Meneses López, Salvatore Grosso, Nathalie Guffon-Fouilhoux, Julia Hennermann, Tarekegn G. Hiwot, Simon Jones, Sandra Kingma, Veroniki Komninaka, Elena Martín-Hernández, Esmeralda Martins, Diana Miclea, György Pfliegler, Esmeralda Rodrigues, Dariusz Rokicki, Dominique Roland, Frank Rutsch, Alessandro Salviati, Ivailo Tournev, Kurt Ullrich, Peter M. van Hasselt, Suresh Vijay, Natalie Weinhold, Peter Witters, and Jiri Zeman. The european reference network for metabolic diseases (metabern) clinical pathway recommendations for pompe disease (acid maltase deficiency, glycogen storage disease type ii). Orphanet Journal of Rare Diseases, Nov 2024. URL: https://doi.org/10.1186/s13023-024-03373-w, doi:10.1186/s13023-024-03373-w. This article has 28 citations and is from a peer-reviewed journal.

  2. (moschetti2024mutationspectrumof pages 1-2): Marta Moschetti, Alessia Lo Curto, Miriam Giacomarra, Daniele Francofonte, Carmela Zizzo, Elisa Messina, Giovanni Duro, and Paolo Colomba. Mutation spectrum of gaa gene in pompe disease: current knowledge and results of an italian study. International Journal of Molecular Sciences, 25:9139, Aug 2024. URL: https://doi.org/10.3390/ijms25179139, doi:10.3390/ijms25179139. This article has 9 citations.

  3. (prater2012theemergingphenotype pages 1-3): Sean N. Prater, Suhrad G. Banugaria, Stephanie M. DeArmey, Eleanor G. Botha, Erin M. Stege, Laura E. Case, Harrison N. Jones, Chanika Phornphutkul, Raymond Y. Wang, Sarah P. Young, and Priya S. Kishnani. The emerging phenotype of long-term survivors with infantile pompe disease. Sep 2012. URL: https://doi.org/10.1038/gim.2012.44, doi:10.1038/gim.2012.44. This article has 226 citations and is from a highest quality peer-reviewed journal.

  4. (OpenTargets Search: Pompe disease-GAA): Open Targets Query (Pompe disease-GAA, 43 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

  5. (moschetti2024mutationspectrumof pages 2-3): Marta Moschetti, Alessia Lo Curto, Miriam Giacomarra, Daniele Francofonte, Carmela Zizzo, Elisa Messina, Giovanni Duro, and Paolo Colomba. Mutation spectrum of gaa gene in pompe disease: current knowledge and results of an italian study. International Journal of Molecular Sciences, 25:9139, Aug 2024. URL: https://doi.org/10.3390/ijms25179139, doi:10.3390/ijms25179139. This article has 9 citations.

  6. (uribecarretero2024lysosomaldysfunctionconnecting pages 14-16): Elisabet Uribe-Carretero, Verónica Rey, Jose Manuel Fuentes, and Isaac Tamargo-Gómez. Lysosomal dysfunction: connecting the dots in the landscape of human diseases. Biology, 13:34, Jan 2024. URL: https://doi.org/10.3390/biology13010034, doi:10.3390/biology13010034. This article has 15 citations.

  7. (leonastudillo2023currentavenuesof pages 11-12): Carmen Leon-Astudillo, Prasad D. Trivedi, Ramon C. Sun, Matthew Gentry, Barry J. Byrne, and Manuela Corti. Current avenues of gene therapy in pompe disease. Jul 2023. URL: https://doi.org/10.1097/wco.0000000000001187, doi:10.1097/wco.0000000000001187. This article has 23 citations and is from a peer-reviewed journal.

  8. (unnisa2022genetherapydevelopments pages 2-3): Zeenath Unnisa, John K. Yoon, Jeffrey W. Schindler, Chris Mason, and Niek P. van Til. Gene therapy developments for pompe disease. Biomedicines, 10:302, Jan 2022. URL: https://doi.org/10.3390/biomedicines10020302, doi:10.3390/biomedicines10020302. This article has 71 citations.

  9. (gragnaniello2023lightandshadows pages 1-2): Vincenza Gragnaniello, Chiara Cazzorla, Daniela Gueraldi, Andrea Puma, Christian Loro, Elena Porcù, Maria Stornaiuolo, Paolo Miglioranza, Leonardo Salviati, Alessandro P Burlina, and Alberto B Burlina. Light and shadows in newborn screening for lysosomal storage disorders: eight years of experience in northeast italy. International Journal of Neonatal Screening, Dec 2023. URL: https://doi.org/10.3390/ijns10010003, doi:10.3390/ijns10010003. This article has 36 citations.

  10. (wang2025effectofnewborn pages 1-2): Xin Wang, Yun Sun, Xian-Wei Guan, Yan-Yun Wang, Dong-Yang Hong, Zhi-Lei Zhang, Ya-Hong Li, Pei-Ying Yang, Tao jiang, and Zheng-feng Xu. Effect of newborn genomic screening for lysosomal storage disorders: a cohort study in china. Genome Medicine, May 2025. URL: https://doi.org/10.1186/s13073-025-01483-z, doi:10.1186/s13073-025-01483-z. This article has 2 citations and is from a highest quality peer-reviewed journal.

  11. (cohen2022inuteroenzymereplacement pages 12-14): Jennifer L. Cohen, Pranesh Chakraborty, Karen Fung-Kee-Fung, Marisa E. Schwab, Deeksha Bali, Sarah P. Young, Michael H. Gelb, Hamid Khaledi, Alicia DiBattista, Stacey Smallshaw, Felipe Moretti, Derek Wong, Catherine Lacroix, Dina El Demellawy, Kyle C. Strickland, Jane Lougheed, Anita Moon-Grady, Billie R. Lianoglou, Paul Harmatz, Priya S. Kishnani, and Tippi C. MacKenzie. In utero enzyme-replacement therapy for infantile-onset pompe’s disease. New England Journal of Medicine, 387:2150-2158, Dec 2022. URL: https://doi.org/10.1056/nejmoa2200587, doi:10.1056/nejmoa2200587. This article has 136 citations and is from a highest quality peer-reviewed journal.

  12. (parenti2024theeuropeanreference pages 22-23): Giancarlo Parenti, Simona Fecarotta, Marianna Alagia, Federica Attaianese, Alessandra Verde, Antonietta Tarallo, Vincenza Gragnaniello, Athanasia Ziagaki, Maria Jose’ Guimaraes, Patricio Aguiar, Andreas Hahn, Olga Azevedo, Maria Alice Donati, Beata Kiec-Wilk, Maurizio Scarpa, Nadine A. M. E. van der Beek, Mireja Del Toro Riera, Dominique P. Germain, Hidde Huidekoper, Johanna M. P. van den Hout, Ans T. van der Ploeg, Ivo Baric, Spyros Batzios, Nadia Belmatoug, Andrea Bordugo, Annet M. Bosch, Anais Brassier, Alberto Burlina, David Cassiman, Brigitte Chabrol, Efstathia Chronopoulou, Maria Luz Couce-Pico, Niklas Darin, Anibh M. Das, Francois G. Debray, Patrick Deegan, Luisa M. de Abreu Freire Diogo Matos, Javier De Las Heras Montero, Maja Di Rocco, Dries Dobbelaere, Francois Eyskens, Ana Ferreira, Ana M. Gaspar, Serena Gasperini, Antonio González-Meneses López, Salvatore Grosso, Nathalie Guffon-Fouilhoux, Julia Hennermann, Tarekegn G. Hiwot, Simon Jones, Sandra Kingma, Veroniki Komninaka, Elena Martín-Hernández, Esmeralda Martins, Diana Miclea, György Pfliegler, Esmeralda Rodrigues, Dariusz Rokicki, Dominique Roland, Frank Rutsch, Alessandro Salviati, Ivailo Tournev, Kurt Ullrich, Peter M. van Hasselt, Suresh Vijay, Natalie Weinhold, Peter Witters, and Jiri Zeman. The european reference network for metabolic diseases (metabern) clinical pathway recommendations for pompe disease (acid maltase deficiency, glycogen storage disease type ii). Orphanet Journal of Rare Diseases, Nov 2024. URL: https://doi.org/10.1186/s13023-024-03373-w, doi:10.1186/s13023-024-03373-w. This article has 28 citations and is from a peer-reviewed journal.

  13. (unnisa2022genetherapydevelopments pages 18-19): Zeenath Unnisa, John K. Yoon, Jeffrey W. Schindler, Chris Mason, and Niek P. van Til. Gene therapy developments for pompe disease. Biomedicines, 10:302, Jan 2022. URL: https://doi.org/10.3390/biomedicines10020302, doi:10.3390/biomedicines10020302. This article has 71 citations.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 9
Resolved 9
Unresolved (possible confabulation) 0
Unverifiable 0
References weighed for topical relevance 9
On topic 6
Off topic 0

All extracted references resolved successfully.